



Dr PD Aude Ambresin

H-Index: 26

Medical Retina Referent,

Swiss Visio Montchoisi, Centre B ISFM, Lausanne, Switzerland

Head of the Swiss Visio Retina Research Center

EVICR clinical site n°136

Swiss Visio Montchoisi

Av. Servan 38
1006 Lausanne
058 274 22 00

aambresin@swissvisio.net



Table of contents

Memberships2

Teaching.....2

Conferences.....4

Clinical Research.....21

Publications.....24

Manuscript review for journals.....31

Broadcast media.....32

Honors.....32

Consultancy.....

Expertise.....

Collaborations.....

Academic University Titles

- Certificate of Advanced Studies in Hospital Leadership. University of Neuchatel; 2022; Neuchatel, Switzerland.
- PD Privat Docent. Medical Faculty, University of Lausanne; Lausanne, Switzerland.
- MER type 1, Research and teaching master. Medical Faculty of the University of Lausanne; 2009-2021; Lausanne, Switzerland.

Education

2015-2023	Good Clinical Practice certificate and updates, according to the latest International Conference on Harmonisation E6 Guidelines. CHUV; Lausanne, Switzerland.
2005	Specialist FMH in Ophthalmic Surgery
2004	Specialist FMH in Ophthalmology
2003-2004	Fellowship Retina, Prof A Bird. Moorfields Eye Hospital; London, United Kingdom.
2003	Medical Doctor, MD Thesis. University of Lausanne; Lausanne, Switzerland.
1998	US medical exam ECFMG, ID 0-581-253-2.
1996	Diploma of Medicine. University of Lausanne; Lausanne, Switzerland.

Postgraduate Professional Experience

2022-present	Medical Retina Referent. Swiss Visio Montchoisi; Lausanne, Switzerland.
2017-2024	Associate Founder. RétinElysée (Private Retina Center); Lausanne, Switzerland.
2008-2019	Consultant, Medical Retina Unit. <i>Hôpital ophtalmique Jules-Gonin</i> (University Eye Hospital); Lausanne, Switzerland.
2004-2017	Senior Physician, Co-head of the Medical Retina Department. <i>Hôpital ophtalmique Jules-Gonin</i> (University Eye Hospital); Lausanne, Switzerland
2004	Senior resident Ophthalmology, Prof. L Zografos. <u><i>Hôpital ophtalmique Jules-Gonin</i></u> (University Eye Hospital); Lausanne, Switzerland.
2003-2004	Fellowship Retina, Prof. A. Bird. Moorfields Eye Hospital; London, United Kingdom.
1999-2002	Residency, Ophthalmology, Prof. L Zografos, <i>Hôpital ophtalmique Jules Gonin</i> (University Eye Hospital); Lausanne, Switzerland.

Memberships

- American Academy Ophthalmology (AAO)
- American Society of Retinal Specialist (ASRS)
- Association for Research in Vision and Ophthalmology (ARVO)
- Barometer Ambassador Committee (2023)
- European Society of Retina Specialists (Euretin)
- European for Vision and Eye Research (EVER)
- Foederatio Medicorum Helveticorum (FMH) (Swiss Medical Association)
- French Ophthalmologists Society (SFO)
- Genolier Innovation Network (GIN)
- International Ocular Circulation Society (IOCS)
- International Retinal Imaging Society (IntRIS)
- Jules-Gonin Alumni Association, Former Vice President
- Macula Society
- Roche Ophthalmology Network, Core Member
- Society for Artificial Intelligence in Vision and Ophthalmology (SAIVO)
- Swiss Society of Ophthalmology (SSO), Member of the Scientific Commission
- Swiss Vitreoretinal Group (SVRG)
- Vision Academy

- Vision For All Foundation, Member of the Executive Committee

Teaching

Medical Faculty, University of Lausanne, Switzerland

- Teaching of courses:
 - Ambresin, A. (every year since 2015) Gène et Vision [University course M1] [2022 evaluation: 100% satisfaction]. Medical Faculty, University of Lausanne, Switzerland
 - Ambresin, A. (2010-2017) Vascular occlusive retinal diseases, diabetic retinopathy, AMD [University course M1]. Medical Faculty, University of Lausanne, Switzerland
- Supervision of master's thesis in Medicine for the following students:
 - Dr Körpe Dilsah (2019). Influence des variations des temps circulatoires rétiens et choroïdiens mesurés en angiographie avec produit de contraste sur l'analyse quantitative obtenue en OCT-angiographie.
 - Dr Gillmann Kevin (2018). Microinvasive glaucoma surgery: study of the efficacy, safety profile and quality of life impact of Istent injection micro bypass stents in patients suffering from open angle glaucoma. Thesis accepted in 2020.
 - Dr Kuonen Anne (2017). Evaluation of perifoveolar capillary changes using OCT angiography in diabetic retinopathy. Thesis accepted in 2020.
 - Dr Zouari Malek (2016). Factors influencing peroperative pain in intravitreal injections.
 - Dr Nguyen Isabelle (2016). Factors influencing peroperative pain in intravitreal injections.
 - Dr Ladaïque Myriam (2015-2015). Long term results of CNV high myopic eyes.
- Supervision of doctorate's thesis in Medicine for the following students:
 - Dr Vallée Rodolphe (2022). Cardiovascular risk prediction by artificial neural networks using dye-based angiography and optical coherence tomography angiography data. Thesis accepted in 2024.

Swiss Visio Montchoisi B Center¹, Lausanne, Switzerland

- Teaching of courses:
 - Angiography
 - Fluorescein and OCT
 - Journal Club Retina
 - Retinal Circulation, Vein Occlusion, and Diabetic Retinopathy
 - Retinal Imagery
- Supervision of the following Medical Retina Fellows:
 - Dr Thomas Lescure 2026
 - Dr Joseph Fang 2025-2026
 - Dr Konstantinos Kitsos-Kalyvianakis 2025
 - Dr Sila Bekiroglu 2025-2026
 - Dr Nicolo Bartolomeo 2024-2025
 - Dr Sila Bekiroglu 2025-2026
 - Dr Nicolo Bartolomeo 2024-2025
 - Dr Alexandre Deglise 2024
 - Dr Mihaela Chitoroaga, 2023-2024

¹ as recognised by the Swiss Medical Federation (FMH)

- Dr Nicolas Owlya, 2022-2023
- Dr Mickael Barbosa, 2022-2023
- Dr Coraline Calci, 2021-2022
- Dr Georgios N Tsiropoulos 2020
- Dr Vasilea Chatzistergiou 2019
- Dr Giorgio Bravetti 2018
- Dr Ioannis Papasavvas 2017-18
- Dr Sacha Naso 2016-2017
- Dr Marta Zola 2016-2017
- Dr Filippo Fabro 2015-2016
- Dr Ali Dirani 2014-2015
- Dr Christina Gianniou 2013-2014
- Dr Angeliki Deli 2012-2013

Jules Gonin Eye Hospital, Lausanne, Switzerland

- Teaching of courses:
 - Gène et Vision

Large audience

- Ambresin A, Bekiroglu S, Chitoroaga M. *Dégénérescence maculaire liée à l'âge : la cécité est-elle une fatalité ?* Presented at: Connaissance 3, Université des seniors; 2025 Jan 1; La Tour de Peilz, Switzerland.
- *Dégénérescence maculaire liée à l'âge: la cécité est-elle une fatalité ?* Connaissance 3, Université des seniors; 2023 Jan 23; Yverdon-les-Bains, Switzerland.
- Formation SD-21-1-22. Espace Compétences; 2021 Dec 1.
- FBM optional course. 2021 Nov 11.

Others

- Gerendas B, Ambresin A, Degli Esposti S, Lukić M, Seres A. Co-hosts of: Imaging of Retinal Diseases. EURETINA Educational Webinar; 2024 Jul 16; Online.
- *Les complications du diabète - Rétinopathie*. Cours pour expert·e en conseil de diabétologie. Hopital de Lavaux; 2023 Nov 15 and 2024 Dec 12; Cully, Switzerland.
- nAMD and Pachychoroid and Subtypes of Namd and Treatment and New Treatment Options. Forum für medizinische Fortbildung (FOMF) Ophthalmologie Update Refresher; 2023 Jun 8; Zurich, Switzerland.
- Euretina Insight interactive course, e-learning module on OCTS in Age-Related Macular Degeneration.
- International Thesis supervision for: Dr Jorge Ruiz Medrano. Study of the Choroid of Healthy Population Using Swept-source Optical Coherence Tomography. Universita Complutens; 2017; Madrid, Spain.

Congres and conferences

As organiser

- Ambresin A, Mantel I. Organisers of: Atelier pratique en imagerie oculaire (APIO) [Practical workshop in ocular imaging]. 2025 Nov 6; Lausanne, Switzerland.
- Ambresin A. Organiser of: Angiography [Workshop]. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2025 Aug 27-29; Basel, Switzerland.
- Ambresin A, Mantel I. Organisers of: *Atelier pratique en imagerie oculaire* in collaboration with Retina Vision and Swiss Visio Network; 2024 Nov 7; Lausanne, Switzerland.
- Ambresin A. Theoretical sessions: Imaging of progression biomarkers in geographic atrophy (*Ateliers pratiques : Biomarqueurs de l'atrophie géographique en imagerie : quels indicateurs de progression ?*). VuExplorer Institute, Ophthalmic Imaging: from Theory to Current Practice; 2024 Oct 4; Paris, France
- Ambresin A, Mérinat A, Comte S, Dutruy-Cheneaux C. Conférence publique : « J'ai un diabète, je vois très bien. Alors pourquoi faire contrôler mes yeux ? ». Swiss Visio et l'Ensemble Hospitalier de la Côte. 2024 Sep 26; Lausanne, Switzerland.
- Ambresin A, Donati G. Organisers of: Santen Hands on Eye; 2023 Dec 7; Lausanne, Switzerland.
- Ambresin A, Sofra D. Organisation of: Le défi des fluctuations du diabète : point de vue de l'ophtalmologue et du diabétologue. Swiss Visio Network conference; 2023 Nov 15; Lausanne,
- Principal organiser of: Imaging I, Postgraduate Training in Ophthalmic Imaging; 2022 Jun 30 and Nov 10; Lausanne, Switzerland.
- Plenary symposium at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2021 Aug 27; Saint Gall, Switzerland.
- Moderator for: IOCS retinal OCTA case conference: Europe and Middle East Edition. The International Ocular Circulation Society; 2021 Jul 16; Online meeting.
- Principal organiser of: Imaging I, Postgraduate Training in Ophthalmic Imaging. 2021 Jun 3 and Nov 11; Lausanne, Switzerland.
- Plenary Session Retina: The Opening up to New Perspectives in Clinical Practice; SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2020 Aug 27, Lausanne, Switzerland.
- Medical retina and glaucoma. Spring seminar. Dr Ambresin and Dr Sunaric Megevand Coppet, Switzerland, 2 April 2020.
- Imaging I, postgraduate training in ophthalmic Imaging, 2020 June 11th and 5 November 2020, Principal organiser, Hotel de la Paix, Lausanne, Switzerland.
- Ambresin A, Coscas F. [Organisers]. Instructional Course 3: Influence of OCT in Daily Clinical Practice. Euretina; 2019 Oct; Paris, France.
- Imaging I, postgraduate training in ophthalmic Imaging, 2019 June 20th and October 3rd, Principal organiser, Hotel de la Paix, Lausanne, Switzerland.
- Imaging I, postgraduate training in ophthalmic Imaging, 2018 September 13th and November 15th, Principal organiser, Hotel de la Paix, Lausanne, Switzerland.
- When should I refer my patient? medical retina and glaucoma. Fall seminar. Coppet, Switzerland, 4th of October 2018.
- SIS EVER Nice Sept 2018: Ischemic ocular diseases: raise the red flag!
- Instructional Course 45, Euretina Sept 2018, "Influence of OCT in daily clinical practice", Organisers: Aude Ambresin, Florence Coscas.
- SIS EVER Nice 29th of Sept 2017: Current contribution of OCT in clinical practice
- Instructional Course 45, Euretina Sept 2017, "Influence of OCT in daily clinical practice", Organisers: Aude Ambresin, Florence Coscas

- Instructional Course 11, Euretina 2016, 2017, “Age-Related Macular Degeneration : Beyond Anti-VEGF Therapy”, Organisers: Aude Ambresin, Irmela Mantel, Thomas Wolfensberger
- How OCT influences our clinical decision. Jeudi de Jules Gonin. Organiser. 19th January 2017
- Plenary Session: vascular occlusive emergencies in Retina; SOG/SSO Swiss Society of Ophthalmology; 2016 Sep; Interlaken, Switzerland.

As invited speaker²

- Ambresin A. Quelles indications de l'angiographie à la fluoresceine à l'ère de l'OCTA ultra-grand champ. Presented at: 132nd International Congress of the French Ophthalmology Society (SFO); 2026 May 9–11; Paris, France.
- Bekiroglu S. Analyse basée sur l'intelligence artificielle des résultats structurels avant et après l'initiation des injections intravitréennes de pegcetacoplan chez des patients atteints de dégénérescence maculaire liée à l'âge sèche : série de cas. Rapid-fire presentation in: 132nd International Congress of the French Ophthalmology Society (SFO); 2026 May 9–11; Paris, France.
- Bartolomeo N. OCT-angiographie à champ ultra-large pour l'analyse de l'anatomie vasculaire choroïdiennes chez les patients atteints de chorioretinopathie séreuse centrale. Rapid-fire presentation in: 132nd International Congress of the French Ophthalmology Society (SFO); 2026 May 9–11; Paris, France.
- Ambresin A. OCTA ultra-grand champ vs. angiographie ultra-grand champ. In: L'ère de l'imagerie Ultra Grand Champ [Webinar]. Lundi de Créteil; 2026 Apr 27; Online.
- Ambresin A, Kowalczyk L, Gallo Castro D, Chitoroaga M, Bekiroglu S. Adaptive Optics Flood-Illumination Reveals Junctional Microstructure Beyond Conventional Imaging in Geographic Atrophy due to Age-Related Macular Degeneration. Presented at: The Macula Society Annual Meeting; 2026 Feb 25-28; San Diego, CA.
- Moshfeghi A, Rahimy E, Javaheri M, Lai TYY, Singer M, Zhang X, Machewitz T, Ambresin A, Wong DT, Korobelnik JF, Zarranz-Ventura J, Leal S; PULSAR investigators. Pigment Epithelial Detachment Outcomes with Aflibercept 8 mg Versus Aflibercept 2 mg in the PULSAR Trial: A 96-Week Post Hoc Analysis. Presented at: The Macula Society Annual Meeting; 2026 Feb 25-28; San Diego, CA.
- Lai TY, Singer MA, Zhang X, Machewit T, Ambresin A, Wong DT, Korobelnik JF, Zarranz-Ventura J, Leal S. Pigment Epithelial Detachment Outcomes with Aflibercept 8 mg Versus Aflibercept 2 mg in the PULSAR Trial: a 96-Week Post Hoc Analysis. Speaker for: 129th Annual Meeting of the Japanese Ophthalmological Society; 2026 Apr 17-20; Tokyo, Japan.
- Ambresin A, Gurbaxani A. Chairs for: Speakers' Corner. Chairs for: 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7 Sep; Paris, France.
- Lai TY, Singer MA, Zhang X, Machewit T, Ambresin A, Wong DT, Korobelnik JF, Zarranz-Ventura J, Leal S. Pigment Epithelial Detachment Outcomes with Aflibercept 8 mg Versus Aflibercept 2 mg in the PULSAR Trial: a 96-Week Post Hoc Analysis. Speaker for: 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7 Sep; Paris, France.
- Hasler P, Maloca P, Feltgen N, Ambresin A, Zweifel S, Blaser F. Chairs for: Plenary Symposium: SOG | SSO Case Series. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2025 Aug 27-29; Basel, Switzerland.
- Ambresin A, Menghini M. Chairs for: Rapid Fire | Poster Flash Session I – Retina Vitreous. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2025 Aug 27-29; Basel, Switzerland.

² List includes events since 2016 on.

- Ambresin A. Indirect comparison of the relative effectiveness of faricimab vs aflibercept 8 mg in diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Speaker for: SOG/SSO Swiss Society of Ophthalmology 118th Annual Congress; 2025 Aug 29; Basel, Switzerland.
- Ambresin A. Chair for: Workshop: Understanding the basics and clinical applications of intra-venous dye angiography: a must to be a fully trained ophthalmologist! SOG/SSO Swiss Society of Ophthalmology 118th Annual Congress; 2025 Aug 27; Basel, Switzerland.
- Ambresin A. Color pictures, filters and auto fluorescence imaging [Workshop]. Speaker for: SOG/SSO Swiss Society of Ophthalmology 118th Annual Congress; 2025 Aug 27; Basel, Switzerland.
- Ambresin A. Recommendations for intravitreal injections & safety [Course]. In: Intravitreal Injection (IVI) Course – Theoretical & Practical Part. Speaker for: SOG/SSO Swiss Society of Ophthalmology 118th Annual Congress; 2025 Aug 27; Basel, Switzerland.
- Ambresin A, Bekiroglu S, Kowalczyk L, Chitoroaga M, Behar-Cohen F. Adaptive Optics Flood Illumination (AO-FI) Study of Drusen Patterns. 11th Annual Pacific Retina Club & 12th Annual International Retinal Imaging Symposium (IntRIS) Meeting; 2025 Jun 5-7; Los Angeles, United States of America.
- Ambresin A, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni AC, Barry PM, Bekiroglu S, Kitsos-Kalyvianakis K, Crozat B, Bartolomeo N. AI integration in research, clinical setting and medical education: A pilot experience towards age related macular degeneration (AMD) management. Delegation of Roche Pharma Switzerland at the Genolier Innovation Hub; 2025 May 21; Genolier, Suisse.
- Ambresin A. *ICG verstehen und interpretieren*. Ophthalmology Update Refresher of the Forum Medizin Fortbildung (FOMF); 2025 May 24; Zurich, Switzerland. [Evaluation by participants available on request]
- Chitoroaga M, Ambresin A. La DMLA, une thérapie personnalisée. Speaker for: Retina Suisse Annual Public Conference; 2025 May 24; Lausanne, Switzerland.
- Ambresin A. Introduire l'IA dans les consultations en rétinie : un leurre ou un réel bénéfice ? 14ème Rencontre ophtalmologique Neuchâtel-Fribourg par le Centre Neuchâtelois d'Ophtalmologie (CNO) et l'Hôpital Fribourgeois (HFR); 2025 Mai 8; Morat, Switzerland.
- Ambresin A. Comparison of Geographic Atrophy (GA) Lesion Measurements and Growth Rates Using Semi-automated and Artificial Intelligence (AI) Software. Speaker for: Ophthalmic Artificial Intelligence Summit 2025. 2025, May 31 2025; Online.
- Chitoroaga M, Ambresin A. XYZ. Speaker for: ABC; 2025 May 24; Lausanne, Switzerland.
- Bartolomeo N, Ambresin A. *Les complications oculaires du diabète*. Speaker for: 'diabètevaud'; 2025 Apr 3; Lausanne, Switzerland.
- Ambresin A. Pegcetacoplan : « breakthrough » ou « fake news » ? La rétinie en pratique : ce qu'il faut savoir en 2025; Centre Ophtalmologique de la Colline; 2025 Fev 20; Geneva, Switzerland.
- Ambresin A. Chair for: Rapid Fire | Poster Flash Session. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 29; Saint Gallen, Switzerland.
- Maloca P, Blaser F, Ambresin A. Chairs and speakers for: Plenary Symposium: Interactive Cases. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 29; Saint Gallen, Switzerland.
- Ambresin A, Cohen S, Borruat F-X, Malclès A, Valmaggia C, Schalenbourg A, Grimaldi G. Presenters for: Angiography cases to describe MCQ. In: Workshop: Angiography. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 28; Saint Gallen, Switzerland.

- Ambresin A. Presenter for: Retinophotography, filters and autofluorescence: what is in it for us? In: Workshop: Angiography. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 28; Saint Gallen, Switzerland.
- Ambresin A. Chair for: Workshop: Angiography. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 28; Saint Gallen, Switzerland.
- Patel PJ, Ambresin A, Koh AH, Singer MA, Hill L, Kotecha A, Margaron P. Extended Interval Treatment Outcomes and Potential Q20W Dosing for Treatment of nAMD With Faricimab: a Post Hoc Analysis of the TENAYA/LUCERNE Trials. Invited speaker at: American Society of Retina Specialists (ASRS) Annual Meeting; 2024 July 17-20; Stockholm, Sweden.
- Ambresin A, Khanani AM, Lai TYY, Lim JI, London N, Kotecha A, Margaron P, Patel S, Souverain A, Willis J, Yang M. Pigment Epithelial Detachment Outcomes With Faricimab vs Aflibercept in Patients With nAMD: Results From TENAYA/LUCERNE. Invited speaker at: American Society of Retina Specialists (ASRS) Annual Meeting; 2024 July 17; Stockholm, Sweden.
- Ambresin A. Photobiomodulation – New Player on the Ground or Great Business Concept? Augenklinik 17. Augenärztliches Symposium; 2024 Jun 27; Zurich, Switzerland.
- Ambresin A, Souied E. Moderators for: Pour nos patients, adoptons dès maintenant les pratiques de demain. 130e Congrès International de la Société Française d'Ophtalmologie (SFO); 2024 May 6; Paris France.
- Ambresin A, Mantel I, Vaclavik V. Experience Exchange, Presentation of Real Cases with Vabysmo. Invited speakers at: Angiopoietin-2 (Ang-2) in Medical Retina Diseases. Swiss Visio Montchoisi; 2024 Feb 1; Lausanne, Switzerland.
- Ambresin A. Traitement de l'atrophie géographique : résultats des études pivotales Oaks and Derby à 2 ans et premières expériences cliniques en suisse romande. Ophtalmologie: innovations thérapeutiques en rétinie médicale et chirurgicale; 2024 Feb 15; Geneva, Switzerland.
- Ambresin A. Retinal Vein Occlusion In Young Patients: Is Special Treatment Required? 8th Congress of the Swiss Academy of Ophthalmology (SAoO); 2024 Apr 10-12; Lucerne, Switzerland.
- Ambresin A. Loosing Vision In Diabetic Maculopathy Without Edema: Does That Make Any Sense? 8th Congress of the Swiss Academy of Ophthalmology (SAoO); 2024 Apr 10-12; Lucerne, Switzerland.
- Prünke C, Ambresin A. Moderation for: Retina Case Club. 8th Congress of the Swiss Academy of Ophthalmology (SAoO); 2024 Apr 10-12; Lucerne, Switzerland.
- Ambresin A, Owyla N. Photobiomodulation bei trockener AMD. SVRG Swiss Retina Update 2023, 2023 Nov 30; Zurich, Switzerland.
- Bechara G, Ambresin A. EPPMA: a propósito de un caso. SCOFT JOVE 2023; 2023 Nov 24; Barcelona, Spain.
- Ambresin A. Workshop given at: Journées de la Rétine Roche (J2R); 2023 Nov 23; Lyon, France.
- Ambresin A. Dry AMD – Licht am Ende des Tunnels? Lichtblicke 17. Ophthalmologie-Symposium; 2023 Nov 09; Bern, Switzerland.
- Ambresin A. Imagerie de la DMLA atrophique. Les Mardis de l'imagerie du Centre Ophtalmologique de Rive; 2023 Oct 31; Geneva, Switzerland.
- Ambresin A. Wet AMD and Faricimab IVI: Fluid Analysis Using OCT in Induction Phase. Conference presentation and moderation at: Ophthalmic Imaging: from Theory to current Practice; 2023 Oct 13; Paris, France.
- Ambresin A. DMLA : La cécité est-elle encore une fatalité? Conference presentation at: Swiss Visio Montchoisi; 2023 Sep 28; Lausanne, Switzerland.
- Ambresin A. Faricimab : un "game-changer"? Retour d'expérience. Conference presentation at: DMLA en Pratique; 2023 Sep 8; Paris, France.

- Giocatni-Aurégan A, Munk M, Ambresin A. Illustrative Cases Presentation: the Answer Was in the Angiography... Spot It! SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2023 Sep 1; Lausanne, Switzerland.
- Ambresin A. Pick Up the OCT Angiography Findings Requiring Dye Angiography. Chair and speaker for: Plenary Symposium: When should I refer my patient for an angiography? SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2023 Sep 1; Lausanne, Switzerland.
- Virtual Workshop on Evaluating Vascular Stabilization with Faricimab: Current Status and Future Directions. The Angiogenesis Foundation; 2023 Jul 12-13; Online.
- Pigment epithelium detachment in age-related macular degeneration. Oftacafé 2023 Retina Symposium; 2023 May 18; Lugano, Switzerland.
- Dégénérescence maculaire liée à l'âge: nouvelles options thérapeutiques. Retina Suisse 44th Annual Meeting; 2023 Apr 29; Bern, Switzerland.
- DMLA : La cécité est-elle encore une fatalité ? Clinique de Montchoisi; 2023 Avr 27; Lausanne, Switzerland.
- Improved retina fluid control with faricimab in phase 3 trials in wet AMD and DME. Symposium d'ophtalmologie, SwissVisio Montchoisi; 2023 Mar 30; Crissier; Switzerland.
- Traitement de l'atrophie géographique: Le Pegcetacoplan bientôt enregistré en Suisse? Résultats des études pivotales Oaks and Derby; Centre Ophtalmologique La Colline; 2023 Mar 30; Geneva, Switzerland.
- Vabysmo First Line - The Early Results: Own OCT examples of treatment-naïve patients. 7th Congress of the Swiss Academy of Ophthalmology; 2023 Mar 2; Lucern, Switzerland.
- Recommendations for intravitreal injection. 7th Congress of the Swiss Academy of Ophthalmology; 2023 Mar 2; Lucern, Switzerland.
- Influence of Retinal and Choroidal Perfusion Times Measured Using Dye Angiography on Quantitative Analysis of OCT-Angiography. 46th Macula Society Annual Meeting; 2023 Feb 17; Miami, United States of America.
- Cas de DMLA avec mauvaise réponse à l'induction: Que faire ? Journée nationale de la Société Française de Rétine; 2023 Jan 21; Paris, France.
- Y-a-t-il une place pour l'utilisation des corticostéroïdes en intravitréen dans la DMLA exsudative? Colloque sur les nouveaux traitements en rétinopathie médicale et chirurgicale; Centre Ophtalmologique La Colline; 2022 Dec 1; Geneva, Switzerland.
- Comparison perfusion time in fluorescein angiography/digital values in OCT-Angiography / Comparaison temps de perfusion en angiographie avec produit de contraste et valeurs métriques de l'OCT angiographie. Ophthalmic Imaging Congress, Paris, September 23rd 2022.
- Perfusion choroïdienne et activité sportive, Swiss Visio Symposium "Les beaux yeux du sport", Lausanne, 22 septembre 2022.
- Have we arrived at the end of the road for advancements in nAMD treatment?, Bayer-sponsored symposium at the Virtual COPHY Global Congress, June 2022.
- Ophthalmology and Covid-19: what we have learnt? Forum pour la formation médicale - WebUp Experten - Forum «Update Ophtalmologie» [Zoom event].. 2021 Oct 21; Online.
- Premières expériences avec le Brolucizumab en Suisse. Formation continue en Ophtalmologie, Clinique de la Colline; 2020 Oct; Geneva, Switzerland.
- Traitements de la DMLA humide en Suisse : Place du Brolucizumab, de l'Aflibercept, du Ranibizumab et du Bevacizumab. Formation continue en Ophtalmologie, Clinique de la Colline; 2020 Oct; Geneva, Switzerland.
- Prise en charge de la maculopathie diabétique : laser micropulsé, anti VEGF ou corticoïdes ? Formation continue en Ophtalmologie, Clinique de la Colline; 2020 Oct; Geneva, Switzerland.
- Pachychoroid: A New Classification and Clinical Applications of Relevant Results of Recent Studies SSO; 2020 Aug 27; Lausanne, Switzerland.

- Diagnostic and treatment of inflammatory neo vessels. SAO; 2019 Mar 8; Luzern, Switzerland.
- Sensitivity of OCT angiography in the detection of choroidal neovascularization in wet AMD in relation to anatomical features on SDOCT. Macula Society; 2019 Feb 14; Bonita Springs, United-States of America.
- Accord entre l'angiographie avec produit de contraste et l'OCT angiographie dans la DMLA néovasculaire, SFR Paris, 19 janvier 2019.
- Biomarqueurs OCT et pathologies maculaires : sine qua non ? Retina Update, Clinique la Colline; 2019 Jan 31; Genève, Switzerland.
- OCT-A : Quand est-elle vraiment utile ? Retina Update, Clinique la Colline; 2019 Jan 31; Genève, Switzerland.
- Influence of structural SD-OCT characteristics in the detection of choroidal neovascularization due to AMD using OCT angiography. OCT 6th Congress; 2018 Dec; Roma, Italy.
- AOP International. Palais Brongniart; 2018 Dec 14-15; Paris, France.
- When should I refer my patient with AMD? Fall seminar. 2018 Oct 4; Coppet, Switzerland.
- Biomarqueurs d'activité en OCTA de la DMLA néovasculaire [OCT angiography in AMD]. Imaging Symposium, Clinique de la Colline; 2018 Jun 21; Geneva, Switzerland.
- Age-related Macular Degeneration. Clinique de Montchoisi; 2018 May 31; Lausanne, Switzerland.
- Polypoidal Cnv In Caucasian Population. Isopt Clinical; 2018 Mar 1-3; Tel Aviv, Israel.
- Maculopathie diabétique : facteurs thérapeutiques systémiques, anti-VEGF, cortisone et laser. Jeudi de Jules Gonin; 2018 Jan 29; Lausanne, Switzerland.
- Biomarkers in clinical diagnosis of wet AMD; Retina French Society, Prof Coscas; 2018 Jan; Paris, France.
- Structural Bscan OCT correlation with OCT Angiography biomarkers of activity in neovascular age related macular degeneration. 2017 Dec 16-17; Rome, Italy.
- Is PRP still needed for diabetic retinopathy? In: Ateliers Pratiques en Ophtalmologie [Webinar]. French Society of Ophthalmology (SFO); 2017 Oct 11; Online.
- OCTA in retinal ischemic disease. Imaging in Ophthalmology; 2017 Oct 13; Paris, France.
- [FR] Effects of intravitreal anti-VEGF on peripheral retinopathy: can we do without PPR?,[Online lecture]. AOP Academy; 2017 Oct 12; Online.
- OCT in wet AMD. Imaging in Ophthalmology; 2017 Oct 11; Paris, France.
- OCT angiography. SEEOS; 2017 Oct 4; Sarajevo, Bosnia and Herzegovina.
- OCT-angiography in every day practice. EVER; 2017 Sep 29; Nice, France.
- Promoting women career through changes of societal stereotypes and academic efficiency indicators. EVER; 2017 Sep 29; Nice, France.
- Aflibercept: designed to be different. Bayer Symposium COPHy; 2017 Mar; Madrid, Spain.
- OCT angiography in AMD. Imaging Symposium; 2017 Feb 2; Geneva, Switzerland.
- Steroids: evolution or revolution. Allergan Symposium; 2016 Nov; Lausanne, Switzerland.
- Tele expertise in Ophthalmology. Retina day; 2016 Nov; Coppet, Switzerland.
- OCT angiography in pediatric sickle cell disease. SIS EVER; 2016 Sep; Nice, France.
- OCT angiography features of AMD. Swiss Society of Ophthalmology; 2016 Aug; Interlaken, Switzerland.
- Reading Center and Telemedicine. EIT Aachen; 2016 Mar; Aachen, Germany.
- New Strategies for Wet AMD; 2016 Feb 11; Vijawada, India.

As free paper speaker

- Ambresin A, Munk MR, Grimaldi G, Hatz K, Machewitz T, Oesch S, Morgan-Warren P, Schmid MK, Zinkernagel MS, et al. Premiers résultats des cohortes nationales les plus précoces de SPECTRUM : résultats de l'aflibercept 8 mg dans la DMLA néovasculaire en Suisse. Free paper presented at: 132nd International Congress of the French Ophthalmology Society (SFO); 2026 May 9–11; Paris, France.
- Bekiroglu S, Ambresin A, Kowalczyk L, Chitoroaga M, Behar-Cohen F. Adaptive Optics Transscleral Flood Illumination (AO-TFI) Study of Drusen Patterns. Free paper presented at: FLORETINA; 4-7 Dec 2025; Florence, Italy.
- Functional and Structural Outcomes of Photobiomodulation (PBM) Therapy in Early and Intermediate Age-related Macular Degeneration (AMD). Free paper presented at: FLORETINA; 4-7 Dec 2025; Florence, Italy.
- Bartolomeo N, Schuetz YP, Nascimbeni AC, Castro DG, Crozat B, Barry MP, Ambresin A. Early Outcome Analysis of Intravitreal Aflibercept 8 mg Treatment in Naïve Patients with Neovascular Age-Related Macular Degeneration Using Artificial Intelligence. Free paper presented at: FLORETINA; 4-7 Dec 2025; Florence, Italy.
- Lange C, Bailey C, Konidaris V, Stahl A, Chaudhary V, Lanzetta P, Oubraham H, Kirchner M, Machewitz T, Allmeier H, Zhang X, Hasanbasic Z, Munk M, Ambresin A. SPECTRUM: *Ergebnisse nach 8 Wochen aus der ersten globalen Real-World-Studie zu Aflibercept 8 mg bei Patienten mit behandlungsnaiver und zuvor behandelter neovaskulärer altersbedingter Makuladegeneration*. Free paper presented at: DOG (German Society of Ophthalmology) Annual Congress; 2025 Sep 25-28; Berlin, Germany.
- Liegl R, Ambresin A, Wong TY, Lanzetta P, Korobelnik JF, Holz FG, Sakamoto T, Sivaprasad S, Patel PJ, Stewart M, Gale R, Zarranz-Ventura J, Schulze A, Machewitz T, Schmidt-Ott UM, Zhang X, Berliner AJ, Chu K, Leal S, Munk M. *PULSAR-Extensionsstudie: 156 Wochen-Ergebnisse bei Patienten mit neovaskulärer altersabhängiger Makuladegeneration (nAMD), die eine Behandlung mit Aflibercept 8 mg erhielten und die von Aflibercept 2 mg auf 8 mg umgestellt wurden*. Free paper presented at: DOG (German Society of Ophthalmology) Annual Congress; 2025 Sep 25-28; Berlin, Germany.
- Ambresin A, Munk MR, Peyla A, Artemiev D, Spitznagel T, Kitay A, Gabathuler F, Eandi C, Garweg JG. Early Real-World Outcomes of Aflibercept 8mg in Treatment-naïve Age-Related Macular Degeneration: A Swiss Retina Research Network Report. Free paper presented at: 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7 Sep; Paris, France.
- Ambresin A, Wong TY, Lanzetta P, Korobelnik JF, Holz FG, Sakamoto T, Sivaprasad S, Patel P, Gale R, Stewart M, Zarranz-Ventura J, Berliner A, Chu K, Munk M. PULSAR Extension: Clinical improvements sustained over 156 weeks with aflibercept 8 mg in patients with neovascular age-related macular degeneration. Free paper presented at: 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7 Sep; Paris, France.
- Garweg JG, Tillmann A, Zweifel S, Grimaldi G, Artemiev D, Spitznagel T, Bartolomeo N, Weinberger A, Kitay A, Heck K, Somfai GM, Hatz K, Eandi C, Munk MR. Early Real-Life Experience with Aflibercept 8mg in Diabetic Macular Edema – a Swiss Retina Research Network Report. Free paper presented at: 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7 Sep; Paris, France.
- Klufas MA, Gerendas BS, Ambresin A, Arevalo JF, Gibson K, Sim D, Yang M. Predictors of Extended Treatment Intervals in Patients With DME Treated With Faricimab in the Phase 3 YOSEMITE/RHINE Trials. Free paper presented at: 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7 Sep; Paris, France.
- Plasencia C, Saad A, Garweg JG, Pfister IB, Munk MR, Eandi CM, Zweifel S, Grimaldi G, Bartolomeo N, Stillenmunkes R, Schild C, Cattaneo J, Gabathuler F, Menghini M, Ambresin A,

Froehlich J, Artemiev D, Weinberger A, Mohamed H, Somfai GM, Hatz K. First-Year Real-World Outcomes of Faricimab in Clinically Significant Diabetic Macular Edema: A Swiss Retina Research Network Report. Free paper presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2025 Aug 27-29; Basel, Switzerland.

- Gale R, Ambresin A, Munk M, Patel PJ, Lanzetta P, Korobelnik J-F, Sivaprasad S, Leal S, Machewitz T, Zhang X. Higher Fluid Control with Aflibercept 8 mg vs Aflibercept 2 mg During Matched Dosing Period Abstract. Free paper submitted at: It Lake City, United States of America. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; 2025 May 4-8; Salty Lake, United States of America.
- Ambresin A, Chitoroaga M, Bartolomeo N, Barry Mamadou P, Pannatier YA, Gallo DA, Nascimbeni AA. Comparison of geographic atrophy (GA) lesion measurements and growth rates using semiautomated and artificial intelligence (AI) software. Free paper presented at: The Macula Society 48th Annual Meeting; 2025 Feb 12-15; Charlotte Harbor, United States of America.
- Ambresin A. Étude comparative de l'atrophie géographique mesurée semi manuellement et par intelligence artificielle dans la DMLA atrophique. Presented at: Journées nationales de la SFRétine; 2025 Jan 25-26; Paris, France.
- Hashimoto R, Ambresin A, Gibson K, Hill L, Sim DA. Predictors of Faricimab Treatment Interval for Diabetic Macular Edema. Presented at: The Japanese Society of Ophthalmic Diabetology Congress; 2025 Jan 25–26; Naha, Japan.
- Ambresin A. Pigment Epithelial Detachment as Long-term Predictors of Functional and Anatomical Outcomes of Intravitreal Faricimab Injections in Naïve Patients With Neovascular Age-related Macular Degeneration. Free paper presented at: FLORetina 12th International Congress on OCT and OCT angiography (ICOOR); 2024 Dec 5-8; Florence, Italy.
- Lanzetta P, Khanani AM, Ambresin A, Avery R, Chaikitmongkol V, Eter N, Gomi F, Lai TYY, Lim JI, London N, Harrell E, Margaron P, Patel S, Souverain A, Yang M. Reduction in Pigment Epithelial Detachments with Faricimab vs Aflibercept in Patients with Treatment-Naïve nAMD: A TENAYA/LUCERNE Post Hoc Analysis. Free paper presented at: FLORetina 12th International Congress on OCT and OCT angiography (ICOOR); 2024 Dec 5-8; Florence, Italy.
- Ambresin A, Gibson K, Sim D, Hill L. Predictors of Extended Treatment Intervals in Patients with DME Treated With Faricimab in the Phase 3 YOSEMITE/RHINE Trials. Free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
- Dhoot DS, Ambresin A, Koh AHC, Patel PJ, Singer M, Dagincourt N, Hill L, Kotecha A, Maragon P. Robust Vision Gains and Anatomical Improvement With Extended Faricimab Dosing and Potential Q20W Dosing in Treatment-Naïve Patients With nAMD in TENAYA/LUCERNE. Free paper presented at: FLORetina 12th International Congress on OCT and OCT angiography (ICOOR); 2024 Dec 5-8; Florence, Italy.
- Koh AHC, Ambresin A, Patel PJ, Singer M, Dagincourt N, Hill L, Kotecha A, Maragon P. Analysis of Extended Interval Treatment Outcomes, Potential for Q20W Dosing and Predictors of Treatment Durability in nAMD With Faricimab From the TENAYA/LUCERNE Trials. Free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
- Ambresin A, Pannatier-Schuetz Y, Nascimbeni AC, Gallo Castro D, Barbosa M. 12-month Outcomes of Intravitreal Injections in Naïve Neovascular Age-related Macular Degeneration: Durability and Retinal Fluids Analysis Using Artificial Intelligence. Audio-narrated free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
- Barbosa M, Owlya N, Pannatier-Schuetz Y, Nascimbeni AC, Gallo Castro D, Ambresin A. One-year Outcomes of Switching from Aflibercept to Faricimab in Resistant nAMD: Durability and Retinal Fluids Analysis Using Artificial Intelligence. Audio-narrated free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.

- Bartolomeo N, Barbosa M, Chitoroaga M, Owlya N, Nascimbeni AC, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Short-term Outcomes of Pigment Epithelial Detachment in Neovascular AMD Patients Switched from Aflibercept to Faricimab. Audio-narrated free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
- Chitoroaga M, Owlya N, Barbosa M, Nascimbeni AC, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Adaptive Optics Transscleral Flood Illumination (AO-TFI) Imaging of Retinal Pigment Epithelium (Rpe): Unveiling Alterations in Dry Amd Retina Using a Novel Segmentation Method. Audio-narrated free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
- Khanani AM, Ambresin A, Avery R, Chaikitmongkol V, Eter N, Gomi F, Lai TYY, Lim JI, London N, Harrell E, Margaron P, Patel S, Souverain A, Yang M. Reduction in Pigment Epithelial Detachment (PED) With Faricimab vs Aflibercept: A Subgroup Analysis of Patients with Large and Serous PEDs From the Pooled Phase 3 TENAYA and LUCERNE Trials. Audio-narrated free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
- Ferrone P, Ambresin A, Avery R, Chaikitmongkol V, Gomi F, Khanani A, Timothy YYL, Lim JI, London N, Harrell E, Maragron P, Patel S, Singer M, Souverain A, Yang M. Response of Large and Serous Pigment Epithelial Detachment to Faricimab Versus Aflibercept in Patients With nAMD: A Subgroup Analysis from TENAYA and LUCERNE. Free paper presented at: Retina Society 57th Annual Scientific Meeting; 2024 Sep 11-15; Lisbon, Portugal.
- Barbosa M, Owlya N, Pannatier-Schuetz Y, Nascimbeni AC, Gallo Castro D, Ambresin A. One Switching from Aflibercept to Faricimab in Resistant nAMD: Durability and Fluids Analysis Using Artificial Intelligence. Free paper presented at: 47th Macula Society Annual Meeting; 2024 Feb 7-10; Palm Springs, United States of America.
- Chaudhary V, Ambresin A, Kotecha A, Willis JR, Souverain A, Shildkrot YE, Swaminathan B, Margaron P. Personalised Faricimab Dosing Increased the Proportion of Patients With nAMD Achieving Q16W Dosing in Year 2 of TENAYA/LUCERNE, While Maintaining Functional and Anatomical Outcomes. Free paper presented at: 127th Annual Meeting of the American Academy of Ophthalmology; 2023 Nov 3-6; San Francisco, United States of America.
- Chaudhary V, Ambresin A, Kotecha A, Willis JR, Souverain A, Shildkrot YE, Swaminathan B, Margaron P. Personalised Faricimab Dosing Increased the Proportion of Patients With nAMD Achieving Q16W Dosing in Year 2 of TENAYA/LUCERNE, While Maintaining Functional and Anatomical Outcomes. Free paper presented at: Retina Society 56th Annual Scientific Meeting; 2023 Oct 13; Lisbon, Portugal.
- Analyse des fluides en OCT durant la phase d'induction chez les patients avec DMLA exsudative traités par injection de faricimab en intra-vitréen. Imagerie en Ophtalmologie : de la théorie à la pratique; Institut de Formation en Imagerie Ophtalmologique; 2023 Oct 13; Paris, France.
- Barbosa M, Owlya N, Nascimbeni A, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Short-term outcomes of switching to intravitreal faricimab in patients with treatment-resistant neovascular age-related macular degeneration. Free paper presented at: 23rd Euretina Congress; 2023 Oct 5-8; Amsterdam, Netherlands.
- K Hatz, A Ambresin, M Schmid, C Prünke, D Barthelmes, T Machewitz, H Allmeier, GM Somfai. Two-year Results From the Swiss Cohort of a Non-interventional Study Investigating Real-world Proactive Dosing Regimens With Intravitreal Aflibercept. Free paper presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2023 Sep 1; Lausanne, Switzerland.
- Barbosa M, Owlya N, Nascimbeni A, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Personalised Faricimab Dosing Increased the Proportion of Patients With nAMD Achieving Q16W Dosing in Year 2 of TENAYA/LUCERNE, While Maintaining Functional and Anatomical Outcomes. Free paper presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2023 Sep 1; Lausanne, Switzerland.

- Influence of retinal and choroidal perfusion times measured using dye angiography on quantitative analysis of OCT-angiography. Ambresin A, Tsiropoulos GN, Vallée R, Gallo Castro D, Körpe D. IOCS; 2021 Sep 24-26; Kyoto, Japan.
- Influence of retinal and choroidal perfusion times measured using dye angiography on quantitative analysis of OCT-angiography. Ambresin A, Tsiropoulos GN, Vallée R, Gallo Castro D, Körpe D. IOCS; 2021 Sep 24-26; Euretina; 2021 Sep 9-12; Virtual meeting.
- Tsiropoulos GN, Vallée R, Calci C, Gallo Castro D, Ambresin A. Patients' opinion on the monitoring of their wet age-related macular degeneration during Coronavirus disease 2019 pandemic and on the importance of telemedicine. G.N. Tsiropoulos, R. Vallée, C. Calci, D. Gallo Castro, A. Ambresin. Euretina; 2021 Sep 9-12; Virtual meeting.
- Tsiropoulos GN, Vallée R, Gallo Castro D, Ambresin A. The Importance of Monitoring Wet Age-related Macular Degeneration Patients During Coronavirus Disease 2019 Pandemic: A retrospective Study of Assessment of Functional and Structural Outcomes. Euretina; 2021 Sep 9-12; Virtual meeting.
- Ambresin A. Free paper session at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2021 Aug 27; Saint Gall, Switzerland.
- Ambresin A. The Spectrum of Disorders Related to Pachychoroid: an EDI-OCT Evaluation. EVER; 2019 Oct 18; Nice, France.
- Ambresin A. OCT and OCT Angiography-Based Management of AMD: Present Indications for the Use of Fluorescein Angiography. EVER; 2019 Oct 18; Nice, France.
- Ambresin A. Imagerie en Ophtalmologie : de la théorie à la pratique; 2019 Oct 4; Paris, France.
- Ambresin A. OCTs in Age-Related Macular Degeneration. Euretina; 2019 Sep; Paris, France.
- Ambresin A. Pathogenesis of Retinal Vascular Diseases. Euretina; 2019 Sep; Paris, France.
- Ambresin A. Aneurysmal Type 1 Neovascularisation. Euretina; 2019 Sep; Paris, France.
- Ambresin A. Reliability of OCTA in the Diagnosis of Fovea Plana. SFO; 2019 May 13; Paris, France.
- A Ambresin, S Roemer. SD-OCT et angio-OCT d'une maculopathie moyenne paracentrale aiguë (PAMM) chez un patient drépanocytaire, à propos d'un cas. SFO; 2019; Paris, France.
- Papasavvas I, Dirani A, Zola M, Pournaras JA, Ambresin A. Influence of structural SD-OCT characteristics in the detection of choroidal neovascularization due to AMD using OCT angiography. Macula Society Annual Meeting; 2019 Feb; Bonita Springs, United States of America.
- Papasavvas I, Dirani A, Zola M, Pournaras JA, Ambresin A. Influence of structural SD-OCT characteristics in the detection of choroidal neovascularization due to AMD using OCT angiography. Euretina; 2018; Vienna, Austria.
- Pournaras JA, Zola M, Papasavvas I, Marchionno L, Ambresin A. Idiopathic epiretinal membrane (ERM) en-face visualisation: comparison of Heidelberg multicolour imaging technique with Optovue en-face OCT. Euretina; 2018; Vienna, Austria.
- Factors influencing pain in postoperative period after anti VEGF intravitreal injections. Euretina; 2017; Barcelona, Spain.
- Comparison of SD OCT and OCTA biomarkers of activity in wet AMD. Euretina; 2017; Barcelona, Spain.
- Macular vasculature of children with sickle cell disease compared to healthy eyes using optical coherence tomography angiography. Euretina; 2016 Sep; Copenhagen, Denmark.
- OCT angiography in branch vein occlusion. Euretina; 2016 Sep; Copenhagen, Denmark.
- Evaluation of perifoveolar capillary changes using OCT angiography in diabetic retinopathy. Euretina; 2016 Sep; Copenhagen, Denmark.
- OCT in sickle cell disease in a pediatric population. Euretina; 2015 Sep; Hamburg, Germany.

- Recurrent macular edema in retinal vein occlusion treated with intravitreal ranibizumab using a modified treat and extend regimen. Euretina; 2014 Sep; London, United Kingdom of Great Britain and Northern Ireland.
- Delayed type hypersensitivity reaction secondary to intravitreal anti –VEGFmAb injections. Club Gonin; 2014 Sep; Zurich, Switzerland.
- Refractory subretinal fluid in patients with neovascular AMD treated with intravitreal Ranibizumab: functional outcome. Euretina; 2013; Hamburg, Germany.
- Delayed type hypersensitivity reaction secondary to intravitreal anti –VEGFmAb injections. Swiss Society of Ophthalmology; 2013 Aug; Locarno, Switzerland.
- Intravitreal Dexamethasone Implant (Ozurdex®) for the Treatment of Macular Edema after Retinal Vein Occlusion in a clinical setting. SOG/SSO Swiss Society of Ophthalmology; 2012 Aug 31; Fribourg, Switzerland.
- 7. Visual prognosis of retinal vein occlusions (RVO) treated by intravitreal antiVEGF injections. SOG/SSO Swiss Society of Ophthalmology; 2011 Sep 2; Interlaken, Switzerland.
- Reproducibility of spectral domain optical coherence tomography and comparison of measurements between TD and SD OCT in neovascular age related macular degeneration SOE/AAO; 2011 Jun 6; Geneva, Switzerland.
- Le traitement de la DMLA exsudative à prédominance hémorragique par injections intravitréennes de ranibizumab. SOG/SSO Swiss Society of Ophthalmology; 2010 Sep; Montreux, Switzerland.
- Retrospective analysis of efficacy of ranibizumab injection in chronic central serous chorioretinopathy (CSCR). SOG/SSO Swiss Society of Ophthalmology; 2009 Sep; Lugano, Switzerland.
- Intravitreal ranibizumab injection for the treatment of large submacular hemorrhage due to age related macular degeneration. Euretina; 2009 May; Nice, France.
- Characterization of a severe autosomal recessive retinal dystrophy caused by an R91W homozygous mutation in the RPE65 gene. SOG/SSO Swiss Society of Ophthalmology; 2003 Sep; Lugano, Switzerland.
- Comparative study between deep sclerectomy with collagen implant and trabeculectomy EGS. European Glaucoma Society; 2000 Jun; London, United Kingdom of Great Britain and Northern Ireland.

As posters presenter³

- J. Fang J, Bartolomeo N, Kowalczyk L, Gallo Castro D, Espourteille J, Ambresin A. OCT-A Morphometric and Qualitative Analysis of Macular Neovascularization in Treatment-Naïve nAMD Treated With Faricimab. E-poster presented at: 132d International Congress of the French Ophthalmology Society (SFO); 2026 9-11 May; Paris, France.
- Garweg J, Ambresin A, et al. Early real-life experience with aflibercept 8mg in diabetic macular edema – a Swiss Retina Research Network report. e-Poster presented at: 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7; Paris, France.
- Benchimol A, Ambresin A, et al. Surgical outcomes of vitrectomy with gas or silicone oil tamponade for giant retinal tears. e-Poster presented at: 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7; Paris, France.
- Bekiroglu S, Ambresin A, Kowalczyk L, Chitoroaga M, Behar-Cohen F. Adaptive Optics Transscleral Flood Illumination (AO-TFI) Study of Drusen Patterns. e-Poster presented at: 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7; Paris, France.
- Bekiroglu S, Ambresin A, et al. Evaluation of geographic atrophy (GA) lesion measurements and growth rates using semi-automated and artificial intelligence (AI) software. e-Poster

³ From 2018 on.

presented at: 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7; Paris, France.

- Bartolomeo N, Ambresin A, et al. Early outcome analysis of intravitreal aflibercept 8mg injections in naïve patients with neovascular age-related macular degeneration using artificial intelligence. e-Poster presented at: 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7; Paris, France.
- Plasencia C, Saad A, Garweg JG, Pfister IB, Munk MR, Eandi CM, Zweifel S, Grimaldi G, Bartolomeo N, Stillenmunkes R, Schild C, Cattaneo J, Gabathuler F, Menghini M, Ambresin A, Froehlich J, Artemiev D, Weinberger A, Mohamed H, Somfai GM, Hatz K. First-Year Real-World Outcomes of Faricimab in Clinically Significant Diabetic Macular Edema: A Swiss Retina Research Network Report. e-Poster presented at: 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7; Paris, France.
- Stahl A, Ambresin A, et al. SPECTRUM: month 6 results from the first global real-world study of aflibercept 8 mg in patients with previously treated neovascular age-related macular degeneration. e-Poster presented at: 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7; Paris, France.
- Kitsos-Kalyvianakis K, Bartolomeo N, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni A, Ambresin A. Early anatomical outcomes of intravitreal aflibercept 8mg in patients with treatment-resistant neovascular age-related macular degeneration using artificial intelligence. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2025 Aug 27-29; Basel, Switzerland.
- Ambresin A, Wells JA, Lupidi M, Keane P, Holekamp N, Leng T, Siedlecki J, Mar F, Gibson K, Margaron P, Paulo T, Buehrer C, Tabano D. Indirect comparison of the relative effectiveness of faricimab vs aflibercept 8 mg in diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2025 Aug 27-29; Basel, Switzerland.
- Ambresin A, Lally DR, Almeida DR, Lu F, Desai A, Chichili G, Petkova-Vamvaka T, Iannaccone A, Moreno-Leon L, Afanaseva A, Khanna H, Jaffe GJ. Post-marketing data supports a differentiated safety profile of avacincaptad pegol (ACP) for geographic atrophy (GA) secondary to AMD. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2025 Aug 27-29; Basel, Switzerland.
- Bekiroglu S, Chitoroaga M, Nascimbeni A, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Evaluation of geographic atrophy (GA) lesion measurements and growth rates using semi-automated and artificial intelligence (AI) software. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2025 Aug 27-29; Basel, Switzerland.
- Combet J, Ambresin A, Gallo Castro D, Chevalley G. SD-OCT description of an acute and resolution phase of outer retinal layers edema secondary to per-operative intracameral cefuroxime injection during cataract surgery. ePoster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2025 Aug 27-29; Basel, Switzerland.
- Spitznagel T, Eandi C, De Oliveira Figueiredo EC, Garweg J, Grimaldi G, Ambresin A, Somfai GM. Deep learning-based longitudinal analysis of microstructural changes in chronic CSCR: a multicenter pilot study. ePoster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2025 Aug 27-29; Basel, Switzerland.
- Arfaoui G, Ambresin A. Two-year treatment outcomes of faricimab in naïve neovascular age-related macular degeneration patients using artificial intelligence. ePoster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2025 Aug 27-29; Basel, Switzerland.
- Gerendas BS, Ambresin A, Arevalo JF, Gibson K, Sim D, Yang M. Predictors of injection numbers in patients with Diabetic Macular Edema (DME) treated with faricimab personalized T&E in the phase 3 YOSEMITE/RHINE trials. Poster presented at: Retina Society 58th Annual Meeting; 2025 Sep 13; Chicago, United-States of America.

- Saad A, Somfai GM, Ambresin A, Ebnetter A, Eandi C, Feltgen N, Hatz K, Menghini M, Munk MR, Weinberger A, Zweifel SA, Schild C, Isabel I, Garweg JG, Grimaldi G. One-year outcomes after switching to faricimab in eyes with pre-treated neovascular age-related macular degeneration: a report from the Swiss Retina Research Network. Poster presented at: Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; 2025 May 4-8, 2025; Salt Lake City, USA.
- Gale R, Ambresin A, Munk M, Patel PJ, Lanzetta P, Korobelnik JF, Sivaprasad S, Leal S, Machewitz T, Zhang X. Greater and more durable fluid resolution with aflibercept 8 mg versus aflibercept 2 mg in the PULSAR trial: A 96-week post-hoc analysis. Poster presented at: Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; 2025 May 4-8, 2025; Salt Lake City, USA.
- Gerendas BS, Ambresin A, Arevalo JF, Gibson K, Sim D, Yang M. Predictors of extended treatment intervals in patients with DME treated with faricimab in the phase 3 YOSEMITE/RHINE trials. Poster presented at: Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; 2025 May 4–8, 2025; Salt Lake City, USA.
- Somfai GM, Turgut F, Tappeiner C, Hatz K, Mantel I, Ambresin A, Donati G, Vivien G, Nagyová D, Pfister I, Schild C, Garweg J. A Swiss Cohort Study on Intravitreal Dexamethasone Implant in Eyes with Diabetic Macular Edema Pretreated by Anti-VEGF Drugs. ePoster presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
- Chitoroaga M, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni AC, Ambresin A. Long-term follow-up of outer retina microdefects (ORMD) in pachychoroid-associated epitheliopathy: a report of two cases. ePoster presented at: SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 28-30; Online.
- Chitoroaga M, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni AC, Ambresin A. Spectral Domain Optical Coherence Tomography (SD-OCT) features in a de novo TFAP2A mutation in a child with branchio-oculo-facial (BOF) syndrome. ePoster presented at: SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 28-30; Online.
- Ferrini W, Schorderet DF, Nicopoulos K, Ambresin A. A novel heterozygous compound mutation in ABCA4 gene linked to late-onset Stargardt disease revealed in the differential diagnosis of early AMD. ePoster presented at: SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 28-30; Online.
- N Bartolomeo N, Déglise A, Pannatier-Schuetz Y, Nascimbeni AC, Gallo Castro D, Ambresin A. Retinal Toxicities of Anticancer Drugs: A Case Series. Poster presented at: SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 29; Saint Gallen, Switzerland.
- Chitoroaga M, Perez Y, Owlya N, Barbosa M, Nascimbeni AC, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Adaptive Optics-enhanced Dual Retinal Layer Imaging and Region Reflectivity-based Segmentation: Unveiling Variances in Healthy and Diseased Retina. Poster presented at: Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; 2024 May 5-9; Seattle, United States of America.
- Chitoroaga M, Perez Y, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni AC, Ambresin A. Spectral Domain Optical Coherence Tomography (SD-OCT) Features in a De Novo TFAP2A Mutation in a Child With Branchio-oculo-facial (BOF) Syndrome. Poster presented at: Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; 2024 May 5-9; Seattle, United States of America.
- Owlya N, Hebben A, Barbosa M, Gallo Castro D, Nascimbeni AC, Pannatier-Schuetz Y, Ambresin A. Functional and Anatomical Outcomes of Patients Treated With Intravitreal Aflibercept for Refractory Diabetic Macular Edema Switched to Faricimab: an Interim Analysis. Poster presented at: 23rd Euretina Congress; 2023 Oct 5-8; Amsterdam, Netherlands.
- Bechara Ghobril A, Pournaras J-A, Ambresin A. Increased Relevance of Clinical and SD-OCT Cardinal Signs Recognition in Patients With the Underdiagnosed Macular Telangiectasia Type 2 (MacTel) Disease. Poster presented at: 23rd Euretina Congress; 2023 Oct 5-8; Amsterdam, Netherlands.

- Barbosa M, Calci C, Owlya N, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni AC, Ambresin A. Acute Intraocular Pressure Elevations Following Intravitreal Anti-VEGF Injections in Patients With Wet AMD: a Preliminary Report. Poster presented at: 23rd Euretina Congress; 2023 Oct 5-8; Amsterdam, Netherlands.
- Ambresin A, Hock Chaun Koh AHC, Singer M, Tadayoni R, Hill L, Souverain A, Kotecha A, Margaron P. The Potential for Q20W Dosing With Faricimab and Extended Treatment Outcomes in Neovascular Age-Related Macular Degeneration: a Post Hoc Analysis of the Pivotal TENAYA/LUCERNE Trials. Poster presented at: 23rd Euretina Congress; 2023 Oct 5-8; Amsterdam, Netherlands.
- Owlya N, Nascimbeni A, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Torpedo Maculopathy: Cases Series Presentation of an Underdiagnosed Rare Condition Using Multimodal Imaging. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress 2023; 2023 Aug 30 - Sep 1; Lausanne, Switzerland.
- Owlya N, Hebben A, Barbosa M, Gallo Castro D, Nascimbeni AC, Pannatier-Schuetz Y, Ambresin A. Functional and Anatomical Outcomes of Patients Treated With Intravitreal Aflibercept for Refractory Diabetic Macular Edema Switched to Faricimab: an Interim Analysis. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress 2023; 2023 Aug 30 - Sep 1; Lausanne, Switzerland.
- Hatz K, Ambresin A, Schmid M, Prünke C, Barthelmes D, Machewitz T, Allmeier H, Márk Somfai G. Two-year Results From the Swiss Cohort of a Non-interventional Study Investigating Real-world Proactive Dosing Regimens With Intravitreal Aflibercept in Patients With nAMD: XTEND Study. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress 2023; 2023 Aug 30 - Sep 1; Lausanne, Switzerland.
- Barbosa M, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni A, Ambresin A. Ocular Manifestations in a Context of Primary Hyperparathyroidism: a Report of Two Cases. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress 2023; 2023 Aug 30 - Sep 1; Lausanne, Switzerland.
- Owlya N, Nascimbeni A, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Torpedo Maculopathy: Cases Series Presentation of an Underdiagnosed Rare Condition Using Multimodal Imaging. Poster presented at: 129e Congrès international de la Société Française d'Ophtalmologie (SFO); 2023 May 6-8; Paris, France.
- Hebben A, Ambresin A. Analyse qualitative en SD-OCT de la réponse thérapeutique immédiate après un switch par faricimab hors indication chez des patients souffrant de néovaisseaux choroïdiens récidivants sous maculaires secondaires à une chorioretinopathie sévère centrale. Poster presented at: 129e Congrès international de la Société Française d'Ophtalmologie (SFO); 2023 May 6-8; Paris, France.
- Bechara Ghobril A, Pournaras J-A, Ambresin A. Increased Relevance of Clinical and SD-OCT Cardinal Signs Recognition in Patients With the Underdiagnosed Macular Telangiectasia Type 2 (MacTel) Disease. Poster presented at: 129e Congrès international de la Société Française d'Ophtalmologie (SFO); 2023 May 6-8; Paris, France.
- Barbosa M, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni A, Ambresin A. Ocular Manifestations in a Context of Primary Hyperparathyroidism: a Report of Two Cases. Poster presented at: 129e Congrès international de la Société Française d'Ophtalmologie (SFO); 2023 May 6-8; Paris, France.
- Vallée R, Ambresin A. Cardiovascular Risk Prediction by Artificial Neural Networks Using Dye-based Angiography and OCT Angiography Data. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2022 Aug 24-26; Basel, Switzerland.
- El Karmy B, Daniela Gallo Castro D, Ambresin A. Retreatment of Recurrent Wet AMD With an Alternative Intravitreal Anti-VEGF Drug After Ocular Inflammation Following Intravitreal Brolucizumab Injection : About Two Cases. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2022 Aug 24-26; Basel, Switzerland.
- Calci C, Gallo Castro D, Mermoud A, Ambresin A. Rapidly Progressive Visual Field Deterioration in a Glaucomatous Patient Treated With Several Anti-VEGF Injections for Neovascular

AMD: a Case Report. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2022 Aug 24-26; Basel, Switzerland.

- Calci C, Gallo Castro D, Mermoud A, Ambresin A. Rapidly Progressive Visual Field Deterioration in a Glaucomatous Patient Treated With Several Anti-VEGF Injections for Neovascular AMD: a Case Report. Poster presented at: 128e congrès international de la Société Française d'Ophthalmologie (SFO); 2022 May 7-9 May; Paris, France.
- Monitoring wet Age related Macular Degeneration patients during Coronavirus disease 2019 pandemic: A retrospective study of assessment of functional and structural outcomes. Georgios N. Tsiropoulos, Rodolphe Vallée, Daniela Gallo Castro, Aude Ambresin. EVER, Nice, 30 September – 2 October 2021.
- Patient opinion on the monitoring of their wet age related macular degeneration during coronavirus disease 2019 pandemic and on the importance of telemedicine. Georgios N. Tsiropoulos, Rodolphe Vallée, Coraline Calci, Daniela Gallo Castro, Aude Ambresin. EVER, Nice, 30 September – 2 October 2021.
- Tsiropoulos GN, Vallée R, Gallo Castro D, Ambresin A. Monitoring Wet Age-related Macular Degeneration Patients During Coronavirus Disease 2019 Pandemic: a Retrospective Study of Assessment of Functional and Structural Outcomes. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2021 Aug 26-27; Saint Gall, Switzerland.
- Meduri E, Tsiropoulos GN, Ribi C, Ambresin A. Efficacy of Tocilizumab in Stabilizing Post-Surgical Inflammatory Refractory Macular Edema: a Report of Two Cases. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2021 Aug 26-27; Saint Gall, Switzerland.
- Pappasavvas I, Ambresin A. Bilateral Ocular Melanocytosis-like Fundus Presentation in Patients With Sectorial Relative Pachychoroid: Case Reports of Six Patients. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2019 Aug 30; Interlaken, Switzerland.
- Chatzistergiou V, Ambresin A. Optical Coherence Tomography Analysis of Cystoid Macular Edema in Retinal Dystrophy Treated With Oral Acetazolamide: 2 Cases. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2019 Aug 30; Interlaken, Switzerland.
- Voide N, Ambresin A. Atypical Retro Internal Limiting Membrane Hemorrhage in Homozygous Sickle Cell Disease. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2019 Aug 30; Interlaken, Switzerland.
- Zola M, Ambresin A, Munier F. Bilateral vascular anomalies in Coats disease suggest concurrent retinal vascular disease. ARVO; 2019; Vancouver, Canada.
- Sherif M, Berthoud J, Ambresin A. OCT-Angiography as a help in the diagnosis of a laser pointer retinal injury. OCTA congress; 2018 Dec; Rome, Italy.
- Voide N, Mantel I, Ambresin A. Atypical retro internal limiting membrane hemorrhage in homozygous sickle-cell disease: a case report. EPOS; 2018; Oslo, Norway.
- Papasavvas I, Ambresin A, Pournaras J-A, Henchoz L, Vaudaux J. Regression of optic disc neovascularization in a patient with Behçet's disease treated with oral corticosteroids and adalimumab. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2018; Fribourg, Switzerland.
- Ambresin A, Bergin C, Naso S. Comparison of SD OCT and OCTA biomarkers of activity in wet AMD. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2018; Fribourg, Switzerland.
- Vasculitis and subfoveal choroidal neovessels in a case of Multifocal Pattern Dystrophy. Roquelaure D, Rossi D, Ambresin A, Guex Crosier Y. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2018; Fribourg, Switzerland.
- Zola M, Ambresin A, Borruat FX, Mantel I. Natural History of PAMM. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2018; Fribourg, Switzerland.

- Sherif M, Berthoud J, Ambresin A. OCT-Angiography as a help in the diagnosis of a laser pointer retinal injury. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2018; Fribourg Switzerland.

As speaker in industry sponsored symposiums⁴

- Ambresin A, Biccias, L. Turning AI Curiosity into Clinical Reality. RetinAI On-demand Webinar; 2026; Online.
- Montero Hernández J, Gale R, Invernizzi A, Ambresin A, Holz F. Speakers for: Breakfast Symposium (Bayer) - Confidence Through Experience: Real-world Insights With Aflibercept 8mg. FLORETINA; 4-7 Dec 2026; Florence, Italy.
- Chang A, Ambresin A, Bailey C. Beyond trials: translating drying to durability in the real world. Speaker for: Bayer Lunch Symposium at the 25th European Society of Retina Specialists (EU-RETINA) Congress; 2025 Sep 4-7 Sep; Paris, France.
- Kitchens J, Chang A, Ambresin A. Clinical conversations: giving reassurance to “seize the day” in the real world. Speaker for: Bayer Lunch Symposium at the 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7; Paris, France.
- Ambresin A, Kitsos-Kalyvianakis K, Bartolomeo N, Crozat B. Turning AI Curiosity into Clinical Reality. Ikerian/RetinAI Diner Symposium at the 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7; Paris, France.
- Hatz K, Ambresin A, Turgut F. Aflibercept 8 mg: from 3 years in studies to Real World Evidence. Bayer Lunch Symposium at SOG/SSO Swiss Society of Ophthalmology Annual Congress; Aug 27-29; Basel, Switzerland.
- Ambresin A. Real-World Impact: Advancing AMD Care with AI. RetinAI On-demand Webinar; 2025; Online.
- Ambresin A. Roche Advisory Board Romandie; 2025 Jun 17; Lausanne, Switzerland.
- Ambresin A. Recent therapeutic advances in nAMD and DME: Real world evidence from Switzerland. Key Invited International Speaker for: Retinal Diseases: Towards New Horizons. Roche; 2025 May 03; Tunis, Tunisia.
- Ambresin A, Bravetti GE. What we’ve learned after 1 year of Aflibercept 8mg in our clinical practice. Bayer Symposium; 2025 Mar 20; Genolier, Switzerland.
- Ambresin A, Bartolomeo N, Crozat B. Real-World Impact Advancing AMD Care with AI. RetinAI Live Series; 2025 Mar 18; Online.
- Ambresin A. Aflibercept 8mg – first experiences in the treatment of nAMD and DME. Bayer Advisory Board Meeting; 2024 Nov 20; Lausanne, Switzerland.
- Ambresin A. Virtual Faricimab Advisory Committee Meeting; 2024 Dec 2; Online.
- Ambresin A. Apellis Advisory Board; 2024 Dec 12; Bern, Switzerland.
- Ambresin A. Roche Advisory Board; 2024 Nov 26; Bern, Switzerland.
- Ambresin A, Bartolomeo N, Chitogara M. Integrating Retinai Discovery clinics in a real-world setting: addressing AMD & GA. RetinAI Discovery Distributor’s Meeting; 2024 Nov 10; Bern, Switzerland.
- Ambresin A, Bartolomeo N, Chitogara M. Integrating Retinai Discovery clinics in a real-world setting: addressing AMD & GA. RetinAI Discovery Distributor’s Meeting; 2024 Sep 21; Barcelona, Spain. Webinar available at: <https://youtu.be/4bOcWsaaUbw>.
- Holekamp N, Ambresin A, Nicholson L, Engelbert M. Revolutionizing First-Line Treatment with Vabysmo. Invited speakers in: Lunch Symposium organized by Roche. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 29; Saint Gallen, Switzerland.

⁴ From 2020 on.

- Feltgen N, Somfai GM, Ambresin A. Panel discussion. Invited speakers in: Lunch Symposium organized by Apellis. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 29; Saint Gallen, Switzerland.
- Ambresin A. GA Patient Management: Practical Considerations. Invited speaker in: Lunch Symposium organized by Apellis. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 29; Saint Gallen, Switzerland.
- Ambresin A. Bayer Advisory Board Meeting on Aflibercept 8mg in Retinal Care. 24th Euretina Congress; 2024 Sep 19; Barcelona, Spain.
- Ambresin A. Moderator for: Astellas Advisory Board Meeting; 2024 Sep 19; 24th Euretina Congress; 2024 Sep 19-22; Barcelona, Spain.
- 130e Congrès International de la Société Française d'Ophtalmologie (SFO); 2024 May 6; Paris France. Moderator for: Symposium Apellis - *Pour nos patients, adoptons dès maintenant les pratiques de demain.*
- 130e Congrès International de la Société Française d'Ophtalmologie (SFO); 2024 May 5; Paris France. Moderator for: Symposium Apellis - *Quelles avancées pour les patients atteints d'atrophie géographique en 2024 ?*
- Get Together with John Kitchens: My Personal Experience with 8 Mg Aflibercept. Bayer Vital Germany; 2024 Mar 18; Online.
- Bayer Advisory Board on 8 mg Aflibercept Launch; 2024 Apr 19-21; Vienna, Austria.
- Ambresin A. Chair for: Apellis InBooth educational session: Geographic Atrophy Contest. 8th Congress of the Swiss Academy of Ophthalmology (SAoO); 2024 Apr 10-12; Lucerne, Switzerland.
- Menghini M, Ambresin A. Vabysmo: Discovering chANGe with Ang-2 in Clinical Practice. Lunch symposium sponsored by Roche. 8th Congress of the Swiss Academy of Ophthalmology (SAoO); 2024 Apr 10-12; Lucerne, Switzerland.
- Ambresin A. Chair for: Lunch symposium sponsored by Bayer. 8th Congress of the Swiss Academy of Ophthalmology (SAoO); 2024 Apr 10-12; Lucerne, Switzerland.
- Ambresin A. Traitement de l'atrophie géographique : résultats des études pivotales Oaks and Derby à 2 ans et premières expériences cliniques en suisse romande. Conference at: Ophtalmologie: innovations thérapeutiques en rétine médicale et chirurgicale; 2024 Feb 15; Geneva, Switzerland.
- Bayer Advisory Board on 8 mg Aflibercept; 2024 Feb 5; Online.
- Bayer Regional Advisory Board on 8 mg Aflibercept; 2023 Dec 6; Lausanne, Switzerland.
- Roche Regional Advisory Board for Ophthalmology; 2023 Nov 22; Lausanne, Switzerland.
- Bayer Advisory Board on 8 mg Aflibercept; 2023 Nov 14; Lausanne, Switzerland.
- Latest Data For 8mg And Real 8 Mg Clinical Experiences. Bayer Global Advisory Board at the 23rd Euretina Congress; 2023 Oct 6; Amsterdam, Netherlands.
- Roche National Advisory Board on Ang-2 Differentiation in Real-World; 2023 Sep 26; Bern, Switzerland.
- Phase III Clinical Data in Geographic Atrophy. Chair and speaker for: Towards a New Era in Geographic Atrophy (GA) Treatment: Insights and Outlook Lunch symposium organised by Apellis. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2023 Sep 1; Lausanne, Switzerland.
- First Hand Experience with Vabysmo. Plenum of National and International Physicians at a Roche-organized Global Event. Discover Change Summit; 2023 Jun 23-24; Athens, Greece.
- Geographic Atrophy (GA) and Challenges in Cost Reimbursement. Apellis Advisory Board; 2023 Jun 6; Lausanne, Switzerland.
- Faricimab: réflexion basée sur l'évidence pour le switch et données de vraie vie. Bayer Board National Rétine; 2023 May 5; Paris, France.

- Apellis Geographic Atrophy Days; 2023 Apr 14-15; Rome, Italy.
- Bayer National Advisory Board on 8 mg Aflibercept; 2023 Jan 23; Bern, Switzerland.
- Apellis Swiss Medical Advisory Board on Geographic Atrophy; 2022 Dec 1; Bern, Switzerland.
- Roche Advisory Board for Ophthalmology; 2022 Nov 24; Lausanne, Switzerland.
- Bayer Advisory Board on Aflibercept; 2022 Nov 7; Lausanne, Switzerland.
- Changing Treatment Landscape – How to Start With the New Options Based on a Risk-benefit Approach? Bayer National Advisory Board on Aflibercept; 2022 Jun 20; Switzerland.
- Novartis Symposium. Swiss Academy of Ophthalmology (SAoO); 2022 Mar 3; Lucerne, Switzerland.
- New Therapeutic Approaches in nAMD and DME. Roche Advisory Board; 2022 Jan 24-25; Switzerland.
- Virtual Diabetic Macular Edema (DME). Novartis Advisory Board; 2021 Nov 25; Switzerland.
- Bayer Advisory Board; 2021 Nov 18; Lausanne, Switzerland.
- Highlights from the EURETINA 2021. Novartis Advisory Board; 2021 Sep 29; Switzerland.
- Bayer Scientific Board; 2020 Oct; Switzerland.
- Pearls in the Anti-VEGF Therapy of Retinal Diseases: From Theory to Practice Differences in Mode of Action of Current Treatments, Actual Insights into Switching Drugs in wAMD. Lunch symposium organized by Bayer. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2020 Aug 28; Lausanne, Switzerland.
- Brolucizumab: From Pivotal Studies to Real World Experience. Lunch symposium organized by Novartis. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2020 Aug 27; Lausanne, Switzerland.
- Novartis Scientific Board; 2020 Jun; Switzerland.

Clinical Research

Multicentric studies

Completed

- PI for: QUASAR (Bayer) - Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion. 2023-2025. Completed.
- S-I for: SANDCAT (Roche) - A Phase III, Multicenter, Randomized, Double Masked, Sham-controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Anti-IL6 in Adult Patients with Uveitic Macular Edema. 2024-2025. Completed.
- PI for: PULSAR (Bayer) - Randomized, Double-Masked, Active-Controlled, Multi-Center Study of Efficacy and Safety of Intravitreal High Dose Aflibercept (8 mg) in Patients with Neovascular Age-Related Macular Degeneration. 2021-2024. Completed.
- INTERCEPT (Aibili) - A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate AMD with and without Early Atrophy to Study Prediction of Disease Progression. Collaboration with: EVICR.net; 2023. Completed.
- Multicentric Retrospective Study on Response to Brolucizumab in Treatment-naïve and Pre-treated Eyes Diagnosed with Wet AMD. Collaboration with: Berner Augenklinik am Lindenhofspital; 2022. Completed.
- Consensus Visual OCT Priming Study Wet AMD. In collaboration with: Institute of Molecular and Clinical Ophthalmology Basel, the University Hospital Basel and the University of Applied Sciences Northwestern Switzerland; 2022. Completed.

- Global nAMD & DR Barometer Survey - A multi-country patient and clinician survey to investigate patients' and clinical peers' perspectives, trends and practice patterns, relevant to the delivery of care for nAMD and DR. 2022. Completed.
- Real-Life Outcomes of Adjunct Intravitreal Dexamethasone Implant (Ozurdex) in Patients Treated with anti-VEGF Drugs for Diabetic Macular Edema and Exudative Age-Related Macular Degeneration. In collaboration with: Berner Augenklinik am Lindenhofspital; 2022. Completed.
- PI for: FALCON (Novartis) - A 52-week, two arm, randomized, open-label, multicenter study assessing the efficacy and safety of two different brolucizumab 6 mg dosing regimens for patients with suboptimal anatomically controlled neovascular age-related macular degeneration. 2021-2022. Completed.
- PI for: The brolucizumab RAPTOR BRVO study RTH258C2301 (Novartis) - An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion. 2019-2021. Completed.
- PI for: XTEND (Bayer) – Evaluation of an eXtended and proacTive dosing regimEn in treatment-Naïve patients with wet age-related macular Degeneration (wAMD). 2019. Completed.
- PI for: (Oxurion) - A Phase 2, randomised, single-masked, active-controlled, multicentre study to evaluate the efficacy and safety of intravitreal THR-317 administered in combination with ranibizumab, for the treatment of diabetic macular oedema. 2018-2019. Completed.
- PI for: Allergan Abicipar Pegol 150998-005 (CEDAR) Study: The Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age related Macular Degeneration. 2016-2017. Completed.
- S-PI for: Efficacy and Safety of RTH258 versus Aflibercept Long Title A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration. 2015-2017. Completed.
- PI for: MONT BLANC - A 12-month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia. Completed.
- PI for: RADIANCE - A 12-month phase III study to evaluate efficacy and safety of two different dosing regimen of 0.5mg ranibizumab vs verteporfin PDT in patients with visual impairment due to choroidal CNV secondary to pathologic myopia. Completed.
- S-PI for: A phase 3, randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista (anti PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration Fovista. Completed.
- S-PI for: OCTAVE - A 24-month phase IIIb randomized multicenter study assessing safety and efficacy of two treatment regimens of 0.5mg ranibizumab intravitreal guided by functional and/or anatomical criteria in patients with neovascular AMD. Completed.
- S-PI for: A 12-month, phase IIIb, randomized, visual acuity assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in TReat and extEND regimen compared to monthly regimen, in patients with neovascular age-related macular degeneration. Completed.
- S-PI for: PROMETEUS - A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven macular edema (ME). Completed.
- S-PI for: MINERVA - A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients

with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV). Completed.

- PI for: CRYSTAL - A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). Completed.
- PI for: BRIGHTER - A 24-month, phase IIIb, open-label, randomized, active controlled, 3-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). Completed.

Ongoing

- PI for: GALAXY (ONL Therapeutics) - A Phase 2 Multicenter, Randomised, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients with Geographic Atrophy (GA) Associated with Age-related Macular Degeneration (AMD). Ongoing.
- PI for: Real-Life Outcomes in Diabetic Macular Edema and Exudative Age-Related Macular Degeneration treated with Faricimab and/or Aflibercept 8mg. Ongoing.
- PI for: VOYAGER (Roche) - Real-world, Long-term Data Collection to Gain Clinical Insights into Roche Ophthalmology Products. Ongoing.
- PI for: SPECTRUM (Bayer) - An Observational Study Program to Investigate the Effectiveness of Aflibercept 8mg Used in nDME and nAMD in a Real-world Setting. Ongoing.
- PI for: AI-based Analysis of Retinal Imaging Data of Real-World Evidence in Switzerland. Ongoing.

Monocentric studies

Completed

- Intravitreal Faricimab in Patients Treated for Refractory Diabetic Macular Edema. 2023-2025. Completed.
- Efficacy and Durability of Faricimab Intravitreal Injections in Naïve Patients With Wet Age-related Macular Degeneration. 2023-2025. Completed.
- Switch From Aflibercept to Faricimab in Patients With Neovascular Age-related Macular Degeneration. 2023-2025. Completed.
- Evolution of Acute Intraocular Pressure Elevations Following Intravitreal Anti-VEGF Injections Over One Year of Treatment.
- Influence of Structural Spectral-domain Optical Coherence Tomography Characteristics in the Detection of Choroidal Neovascularization Due to Age-related Macular Degeneration Using Optical Coherence Tomography Angiography.
- COVID AMD - Tsiropoulos GN, Ambresin A. Patient Opinion on the Monitoring of Their Wet Age-related Macular Degeneration During Coronavirus Disease 2019 Pandemic and on the Importance of Telemedicine. Free paper.
- COVID AMD - The Importance of Monitoring Wet AMD Patients During Covid-19 Pandemic: a Retrospective Study of Assessment of Functional and Structural Outcomes. Published.
- COVID-RV – Five Cases of Retinal Vascular Anomalies After Covid-19: a Case Series. Free paper.
- Fovea Plana / Hypoplasia - Foveal Hypoplasia on Optical Coherence Tomography Angiography: New Perspectives. Published.

- AZM RD - Optical Coherence Tomography Analysis of Cystoid Macular Edema in Retinal Dys-trophy Treated with Oral Acetazolamide: Two Cases. Published.
- Vitamin A Deficiency - Markedly Delayed Night Blindness Due to Vitamin A Insufficiency Sec-ondary to Bowel Resection. Published.

Ongoing

- Photobiomodulation (PBM) therapy in intermediate dry age-related macular degeneration (AMD). 2025-ongoing.
- DREAM OCT - Noninvasive ultrawide field choroidal imaging using swept source OCT to as-sess macular and peripheral choroidal vasculature. 2025- ongoing.
- Optics-Flood Illumination (AO-FI) study of chronic retinal diseases: dry age-related macular degeneration (AMD), central serous chorioretinopathy (CSCR) and non-proliferative diabetic retinopathy (NPDR). 2025-ongoing.
- Evaluation of geographic atrophy (GA) lesion size and growth rates measurements using semiautomated and artificial intelligence (AI) software. 2025-ongoing.
- Real-world observational data on the use of aflibercept 8mg intravitreal injection in patients treated for exudative age-related macular degeneration and diabetic macular edema. 2024-on-going.

Publications

Peer-reviewed scientific papers

- Seppey C, Kaisari E, Anjou M, Eandi CM, Ambresin A, Brézin AP, Guex-Crosier Y, Hoogewoud F. Persistent placoid maculopathy: long term outcomes and prognostic factors. *Retina*. 2026 Jun 26. doi: 10.1097/IAE.0000000000004914. Epub ahead of print. PMID: 42351292.
- Heck K, Hatz K, Cattaneo M, Pfister I, Magnin S, Ruscitti L, Stasik I, Tillmann A, Shamshiev M, Fang J, Weinberger A, Zweifel SA, Garweg JG, Eandi CM, Grimaldi G, Munk MR, Somfai GM, Ambresin A, Feltgen N. Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report. *Ophthalmol Ther*. 2026 Jun 23. doi: 10.1007/s40123-026-01442-w. Epub ahead of print. PMID: 42334530.
- Javaheri M, Sanfilippo CJ, Kasi SK, Chen R, Ruiz-Moreno JM, Shields CL, Saperstein DA, Yuan A, Lujan BJ, Heimann H, Dodeja R, Bergstrom C, Yanik Ö, Berry JL, Nagiel A. Pheno-typic Spectrum of Benign Lobular Inner Nuclear Layer Proliferations: A Multicenter Analysis and Review of the Literature. *Ophthalmol Retina*. 2025 Oct;9(10):1017-1022. doi: 10.1016/j.oret.2025.04.004. Epub 2025 Apr 8. Erratum in: *Ophthalmol Retina*. 2026 Jun;10(6):687. doi: 10.1016/j.oret.2026.04.002. PMID: 40209933; PMCID: PMC12353968. [Reported BLIP case]
- Spitznagel T, Garweg JG, Eandi C, Grimaldi G, Menghini M, Ambresin A, Zweifel S, Somfai GM. Practical Challenges for the Implementation of AI-Based Image Analysis in Ophthalmol-ogy Research: Insights and Recommendations from a Swiss Multicentric Study. *Klin Monbl Augenheilkd*. 2026 Apr;243(4):469-474. doi: 10.1055/a-2802-7192. Epub 2026 Apr 20. PMID: 42008995; PMCID: PMC13095367.
- Tillmann A, Stillenmunkes R, Garweg JG, Cattaneo J, Bartolomeo N, Grimaldi G, Spitznagel T, De Oliveira Figueiredo EC, Ambresin A, Menghini M, Somfai GM, Zweifel S, Fröhlich J, Artemiev D, Ebnetter A, Hatz K, Weinberger A, Pfister IB, Schild C, Eandi C, Munk MR; Swiss Retina Research Network. One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. *Ophthalmol Ther*. 2025 Dec;14(12):3079-3091. doi: 10.1007/s40123-025-01252-6. Epub 2025 Oct 17. Er-ratum in: *Ophthalmol Ther*. 2026 Apr;15(4):1551-1553. doi: 10.1007/s40123-026-01319-y. PMID: 41105325; PMCID: PMC12579096.

- Combet J, Castro DG, Ambresin A. Spectral Domain Optical Coherence Tomography Description of an Acute and Resolution Phase of Outer Retinal Layers Edema Secondary Perioperative Intracameral Cefuroxime Injection in Cataract Surgery. *Klin Monbl Augenheilkd*. 2026 Apr;243(4):479-481. English. doi: 10.1055/a-2773-2987. Epub 2026 Apr 20. PMID: 42008984.
- Lim JI, Ambresin A, Avery RL, Chaikitmongkol V, Eter N, Gomi F, Khanani AM, London NJS, Harrell E, Margaron P, Patel S, Souverain A, Yang M, Lai TYY. Reduction in Pigment Epithelial Detachment Thickness with Faricimab versus Aflibercept 2 mg during Head-to-Head Dosing in TENAYA/LUCERNE. *Ophthalmol Sci*. 2026 Mar 10;6(5):101148. doi: 10.1016/j.xops.2026.101148. PMID: 42005909; PMCID: PMC13084404.
- Spindler J, Artemiev D, Pfister IB, Schild C, Tillmann A, Heck K, Gabathuler F, Ruscitti L, Spitznagel T, Kitsos-Kalyvianakis K, Munk MR, Hatz K, Zweifel SA, Grimaldi G, Somfai GM, Ambresin A, Weinberger A, Eandi CM, Feltgen N, Kitay A, Ebnetter A, Garweg JG. Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report. *Ophthalmol Sci*. 2026 Jan 22;6(4):101087. doi: 10.1016/j.xops.2026.101087. PMID: 41783077; PMCID: PMC12955161.
- Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM. One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. *Ophthalmol Ther*. 2026 Apr;15(4):1375-1388. doi: 10.1007/s40123-026-01344-x. Epub 2026 Mar 4. PMID: 41779364; PMCID: PMC13046877.
- Tillmann A, Stillenmunkes R, Garweg JG, Cattaneo J, Bartolomeo N, Grimaldi G, Spitznagel T, De Oliveira Figueiredo EC, Ambresin A, Menghini M, Somfai GM, Zweifel S, Fröhlich J, Artemiev D, Ebnetter A, Hatz K, Weinberger A, Pfister IB, Schild C, Eandi C, Munk MR; Swiss Retina Research Network. Correction: One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. *Ophthalmol Ther*. 2026 Apr;15(4):1551-1553. doi: 10.1007/s40123-026-01319-y. Erratum for: *Ophthalmol Ther*. 2025 Dec;14(12):3079-3091. doi: 10.1007/s40123-025-01252-6. PMID: 41762378; PMCID: PMC13046922.
- Dinah C, Chang A, Gabrielle PH, Singh R, Zarranz-Ventura J, Saffar I, Bagijn M, Ambresin A. Synergising Macular Function and Structure in Diabetic Macular Oedema to Improve Patient Care: An International Delphi Consensus. *Ophthalmol Ther*. 2026 Mar;15(3):1179-1194. doi: 10.1007/s40123-026-01336-x. Epub 2026 Feb 26. PMID: 41746594; PMCID: PMC12976320.
- Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A, Tillmann A, De Oliveira Figueiredo EC, Spitznagel T, Kitay AM, Gabathuler F, Zweifel S, Kurz-Levin MM, Ebnetter A, Somfai GM, Eandi CM, Munk MR, Ambresin A, Menghini M. One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. *Ophthalmol Ther*. 2026 Mar;15(3):1069-1082. doi: 10.1007/s40123-025-01305-w. Epub 2026 Feb 3. PMID: 41634482; PMCID: PMC12976334.
- Barbosa M, Bartolomeo N, Schuetz YP, Nascimbeni AC, Castro DG, Barry MP, Ambresin A. Loading dose and 12-month outcomes in treatment-naïve patients with neovascular age-related macular degeneration treated with faricimab, with AI-based analysis of fluid dynamics. *Int Ophthalmol*. 2026 Feb 19;46(1):124. doi: 10.1007/s10792-026-04003-z. PMID: 41712059.
- Saad A, Plasencia C, Garweg J, Pfister IB, Munk MR, Eandi CM, Zweifel SA, Grimaldi G, Bartolomeo N, Stillenmunkes R, Schild C, Cattaneo J, Gabathuler F, Menghini M, Ambresin A, Fröhlich J, Artemiev D, Weinberger A, Mohamed H, Somfai GM, Hatz K. First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina

- research network report. *BMJ Open Ophthalmol*. 2026 Jan 30;11(1):e002467. doi: 10.1136/bmjophth-2025-002467. PMID: 41617258; PMCID: PMC12863342.
- Ambresin A, Chaudhary V, Gale R, Koh AHC, London NJS, Patel PJ, Tan ACS, Hill L, Kotecha A, Margaron P, Singer M; TENAYA/LUCERNE Investigators. Potential 20-Week Faricimab Dosing in Wet Age-Related Macular Degeneration. *Ophthalmol Retina*. 2026 Feb 6:S2468-6530(26)00045-X. doi: 10.1016/j.oret.2026.02.001. Epub ahead of print. PMID: 41655766.
 - Owlya N, Barbosa M, Bartolomeo N, Pannatier-Schuetz Y, Nascimbeni AC, Castro DG, Barry MP, Ambresin A. Intravitreal faricimab in patients with refractory diabetic macular edema: 6-month fluid analysis using artificial intelligence. *BMC Ophthalmol*. 2026 Feb 6. doi: 10.1186/s12886-026-04651-w. Epub ahead of print. PMID: 41652390.
 - Bartolomeo N, Kalyvianakis KK, Schuetz YP, Nascimbeni AC, Castro DG, Crozat B, Barry MP, Ambresin A. Early Outcomes of Intravitreal Aflibercept 8 mg in Eyes Previously Treated with Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification. *Ophthalmol Ther*. 2026 Feb;15(2):831-842. doi: 10.1007/s40123-026-01320-5. Epub 2026 Jan 29. PMID: 41612003; PMCID: PMC12901791.
 - Bartolomeo N, Barbosa M, Pannatier Schuetz Y, Castro DG, Nascimbeni AC, Barry MP, Ambresin A. Pigment epithelial detachment as a biomarker for faricimab treatment outcomes in naïve neovascular age-related macular degeneration. *Eur J Ophthalmol*. 2025 Dec 17:11206721251400508. doi: 10.1177/11206721251400508. Epub ahead of print. PMID: 41406248.
 - Barbosa M, Bartolomeo N, Schuetz YP, Nascimbeni AC, Castro DG, Barry MP, Ambresin A. Intravitreal faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration: short and long-term outcomes and assessment of volume dynamics using an artificial intelligence-based tool. *Int J Retina Vitreous*. 2025 Nov 19;11(1):126. doi: 10.1186/s40942-025-00751-9. PMID: 41258038; PMCID: PMC12628855.
 - Zarranz-Ventura J, Ambresin A, Chang A, Dinah C, Holekamp NM, Rocha J, Saffar I, Singh RP. Establishing Expert Consensus on a Unified Decision Framework for Retina Patient Care. *Ophthalmol Ther*. 2025 Nov 15. doi: 10.1007/s40123-025-01269-x. Epub ahead of print. PMID: 41239161.
 - Tillmann A, Stillenmunkes R, Garweg JG, Cattaneo J, Bartolomeo N, Grimaldi G, Spitznagel T, De Oliveira Figueiredo EC, Ambresin A, Menghini M, Somfai GM, Zweifel S, Fröhlich J, Artemiev D, Ebnetter A, Hatz K, Weinberger A, Pfister IB, Schild C, Eandi C, Munk MR; Swiss Retina Research Network. One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. *Ophthalmol Ther*. 2025 Dec;14(12):3079-3091. doi: 10.1007/s40123-025-01252-6. Epub 2025 Oct 17. PMID: 41105325; PMCID: PMC12579096.
 - Bartolomeo N, Schuetz YP, Nascimbeni AC, Castro DG, Crozat B, Barry MP, Ambresin A. Early Outcome Analysis of Intravitreal Aflibercept 8 mg Treatment in Naïve Patients with Neovascular Age-Related Macular Degeneration Using Artificial Intelligence. *Ophthalmol Ther*. 2025 Sep 19. doi: 10.1007/s40123-025-01239-3. Epub ahead of print. PMID: 40971062.
 - Ambresin A, Quist SW, Boer M, Maamari S, Barthelmes D. Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland. *J Med Econ*. 2025 Dec;28(1):1198-1213. doi: 10.1080/13696998.2025.2536420. Epub 2025 Jul 29. PMID: 40692491.
 - Javaheri M, Sanfilippo CJ, Kasi SK, Chen R, Ruiz-Moreno JM, Shields CL, Saperstein DA, Yuan A, Lujan BJ, Heimann H, Dodeja R, Bergstrom C, Yanik Ö, Berry JL, Nagiel A. Phenotypic Spectrum of Benign Lobular Inner Nuclear Layer Proliferations: A Multicenter Analysis and Review of the Literature. *Ophthalmol Retina*. 2025 Oct;9(10):1017-1022. doi: 10.1016/j.oret.2025.04.004. Epub 2025 Apr 8. Erratum in: *Ophthalmol Retina*. 2026 Jun;10(6):687. doi: 10.1016/j.oret.2026.04.002. PMID: 40209933; PMCID: PMC12353968.
 - Hatz K, Ambresin A, Schmid M, Prünke C, Barthelmes D, Machewitz T, Allmeier H, Somfai GM; XTEND Study Group. Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration. *J Clin Med*. 2025 Mar 29;14(7):2370. doi: 10.3390/jcm14072370. PMID: 40217821; PMCID: PMC11989833.

- Grimaldi G, Ambresin A, Pfister IB, Schild C, Plasencia C, Hatz K, Stillenmunkes R, Munk MR, Paris A, Menghini M, Artemiev D, Ebnetter A, Cattaneo J, de Oliveira Figueiredo EC, Eandi CM, Fröhlich J, Feltgen N, Spitznagel T, Somfai GM, Cozzi M, Zweifel S, Weinberger A, Garweg JG. One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. *Ophthalmol Retina*. 2025 Mar 24:S2468-6530(25)00124-1. doi: 10.1016/j.oret.2025.03.015. Epub ahead of print. PMID: 40139459.
- Chitoroaga M, Pannatier Schuetz Y, Gallo Castro D, Nascimbeni AC, Ambresin A. Long-term Follow-up of Outer Retinal Microdefects (ORMDs) in Pachychoroid Pigment Epitheliopathy (PPE) and Sub-sequent Central Serous Chorioretinopathy (CSCR): A Report of Two Cases. *Klin Monbl Augenheilkd*. 2025. DOI: 10.1055/a-2500-5687. Epub ahead of print.
- Bartolomeo N, Déglise A, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni AC, Ambresin A. Retinal Toxicity of Anticancer Drugs: a Case Series. *Klin Monbl Augenheilkd*. 2025. DOI: 10.1055/a-2521-4104
- Ben Ghezala I, Steinberg LA, Sibert M, Lazzarotti A, Ambresin A, Gabrielle PH, Creuzot-Garcher C. Temperature Excursion of Intravitreal Anti-VEGF Agents During Home Storage. *JAMA Ophthalmol*. 2025 Jan 16. doi: 10.1001/jamaophthalmol.2024.5884. Epub ahead of print. PMID: 39820629.
- Turgut F, Somfai GM, Tappeiner C, Hatz K, Mantel I, Ambresin A, Donati G, Guignard V, Nagyová D, Pfister IB, Schild C, Garweg JG. Intravitreal Dexamethasone Implant in Anti-Vascular Endothelial Growth Factor Pretreated Diabetic Macular Edema-A Swiss Cohort Study. *Pharmaceuticals (Basel)*. 2024 Sep 19;17(9):1235. doi: 10.3390/ph17091235. PMID: 39338397; PMCID: PMC11434786.
- Vallée R, Körpe D, Vallée JN, Tsiropoulos GN, Gallo Castro D, Mantel I, Pournaras CJ, Ambresin A. Impact of preocular and ocular circulatory dynamics on the vascular density of retinal capillary plexuses and choriocapillaris. *Graefes Arch Clin Exp Ophthalmol*. 2024 Dec;262(12):3867-3879. doi: 10.1007/s00417-024-06544-4. Epub 2024 Jul 31. PMID: 39083077; PMCID: PMC11608175.
- Barbosa M, Pannatier-Schuetz Y, Nascimbeni AC, Castro DG, Owlya N, Ambresin A. Ocular Manifestations in a Context of Primary Hyperparathyroidism: A Report of Two Cases. *Klin Monbl Augenheilkd*. 2024 Apr;241(4):545-548. doi: 10.1055/a-2243-4802. Epub 2024 Apr 23.
- Owlya N, Barbosa M, Nascimbeni AC, Pannatier-Schuetz Y, Castro DG, Ambresin A, Torpedo Maculopathy: Case Series of an Underdiagnosed and Rare Condition Using Multimodal Imaging, *Klin Monbl Augenheilkd*. 2024 Mar 26. doi: 10.1055/a-2238-7245. Online ahead of print.
- Pietzuch M, Mantel I, Ambresin A, Tappeiner C, Nagyova D, Donati G, Pfister IB, Schild C, Garweg JG. Intravitreal Dexamethasone as a Rescue for Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration with Persistent Disease Activity and High Treatment Demand. *J Ocul Pharmacol Ther*. 2023 Dec 20. doi: 10.1089/jop.2023.0105. Epub ahead of print. PMID: 38117666.
- Karmy BE, Castro DG, Ambresin A. Preventive Inflammation Management with Steroids before Retreatment with Anti-VEGF after Severe Inflammation due to Brolucizumab. *Klin Monbl Augenheilkd*. 2023 Apr;240(4):556-562. English. doi: 10.1055/a-2045-7844. Epub 2023 Apr 25. PMID: 37164395.
- Calci C, Castro DG, Schuetz YP, Mermoud A, Ambresin A. Rapidly Progressive Visual Field Deterioration in a Glaucomatous Patient Treated with Several Anti-VEGF Injections for Neovascular AMD: A Case Report. *Klin Monbl Augenheilkd*. 2023 Apr;240(4):478-480. English. doi: 10.1055/a-2004-5664. Epub 2023 Apr 25. PMID: 37164425.
- Tsiropoulos GN, Vallée R, Calci C, Gallo Castro D, Ambresin A. Patient Perspective on the Monitoring of Their Wet Age-Related Macular Degeneration during Coronavirus Disease 2019: A Retrospective Study. *Medicina (Kaunas)*. 2023 Mar 2;59(3):490. doi: 10.3390/medicina59030490. PMID: 36984491; PMCID: PMC10053385.
- Tsiropoulos GN, Castro DG, Ambresin A. Six Cases of Retinal Vascular Anomalies after Coronavirus Disease 2019: A Case Series. *Klin Monbl Augenheilkd*. 2022 Apr;239(4):537-544. English. doi: 10.1055/a-1771-5695. Epub 2022 Apr 26. PMID: 35472801.

- Tsiropoulos GN, Vallée R, Gallo Castro D, Ambresin A. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes. *J Fr Ophtalmol*. 2022 Oct;45(8):852-859. doi: 10.1016/j.jfo.2022.05.005. Epub 2022 Jul 6. PMID: 35908993; PMCID: PMC9257228.
- Moret E, Ambresin A, Gianniou C, Bijon J, Besse-Hayat C, Bogiatzi S, Hohl D, Spertini F, Mantel I. Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors. *Graefes Arch Clin Exp Ophthalmol*. 2022 Mar;260(3):1005-1014. doi: 10.1007/s00417-021-05353-3. Epub 2021 Sep 16. PMID: 34529134; PMCID: PMC8850288.
- Bravetti GE, Vaudaux J, Pournaras JA, Ambresin A. Persistent Remnants of Dexamethasone Intravitreal Implant Over 24 Months in a Patient Suffering from Anterior and Intermediate Uveitis Associated with Macular Edema. *Klin Monbl Augenheilkd*. 2021 Apr;238(4):454-457. English. doi: 10.1055/a-1384-1056. Epub 2021 Apr 30. PMID: 33930917.
- Chatzistergiou V, Papasavvas I, Ambresin A, Pournaras JC. Prediction of Postoperative Visual Outcome in Patients with Idiopathic Epiretinal Membrane. *Ophthalmologica*. 2021;244(6):535-542. doi: 10.1159/000517193. Epub 2021 Jun 1. PMID: 34062549.
- Zola M, Ambresin A, Zografos L. Optical Coherence Tomography Angiography Imaging of a Congenital Simple Hamartoma of the Retinal Pigment Epithelium. *Retin Cases Brief Rep*. 2021 May 1;15(3):289-293. doi: 10.1097/ICB.0000000000000788. PMID: 30074568.
- Chatzistergiou V, Ambresin A, Borruat FX. Markedly Delayed Night Blindness Due to Vitamin A Insufficiency Secondary to Bowel Resection. *Klin Monbl Augenheilkd*. 2021 Apr;238(4):428-430. English. doi: 10.1055/a-1354-5816. Epub 2021 Feb 22. PMID: 33618384.
- Chatzistergiou V, Cilliers H, Pournaras JA, Ambresin A. Fovea Plana on Optical Coherence Tomography Angiography: New Perspectives. *Retina*. 2021 Jul 1;41(7):1541-1546. doi: 10.1097/IAE.0000000000003046. PMID: 33323906; PMCID: PMC8210783.
- Kuonen A, Bergin C, Ambresin A. Perifoveal capillary changes in diabetic patients and association between severity and type of diabetes, visual acuity, and enlargement of non-flow area in the retinal capillary plexuses. *J Fr Ophtalmol*. 2021 Mar;44(3):367-375. doi: 10.1016/j.jfo.2020.09.005. Epub 2021 Jan 23. PMID: 33494976.
- Gillmann K, Mansouri K, Ambresin A, Bravetti GE, Mermoud A. A Prospective Analysis of iStent Inject Microstent Implantation: Surgical Outcomes, Endothelial Cell Density, and Device Position at 12 Months. *J Glaucoma*. 2020 Aug;29(8):639-647. doi: 10.1097/IJG.0000000000001546. PMID: 32433094.
- Voide N, Mantel I, Ambresin A. Atypical Retro Internal Limiting Membrane Haemorrhage in Homozygous Sickle Cell Disease. *Klin Monbl Augenheilkd*. 2020 Apr;237(4):477-479. English. doi: 10.1055/a-1067-4141. Epub 2020 Feb 3. PMID: 32016938.
- Chatzistergiou V, Papasavvas I, Escher P, Durig J, Vaudaux J, Pournaras JA, Ambresin A. Optical Coherence Tomography Analysis of Cystoid Macular Edema in Retinal Dystrophy Treated with Oral Acetazolamide: Two Cases. *Klin Monbl Augenheilkd*. 2020 Apr;237(4):484-486. English. doi: 10.1055/a-1068-2762. Epub 2020 Feb 24. PMID: 32092772.
- Kheir V, Ambresin A, Mantel I. Multiple Serous Pigment Epithelial Detachments in Association With Major Weight Loss: Case Report and Review of the Literature. *Retin Cases Brief Rep*. 2020 Winter;14(1):72-76. doi: 10.1097/ICB.0000000000000624. PMID: 28834921.
- Roquelaure D, Rossi DC, Ambresin A, Guex-Crosier Y. Vasculitis and Retrofoveal Choroidal Neovessels in a Case of Multifocal Pattern Dystrophy. *Klin Monbl Augenheilkd*. 2019 Apr;236(4):523-525. English. doi: 10.1055/a-0831-2195. Epub 2019 Apr 18. PMID: 30999342.
- Sherif M, Berthoud J, Pournaras JA, Ambresin A. OCT-Angiography as a Help in the Diagnosis of a Laser Pointer Retinal Injury: A Case Report. *Klin Monbl Augenheilkd*. 2019 Apr;236(4):594-597. English. doi: 10.1055/a-0828-7449. Epub 2019 Feb 20. PMID: 30786287.
- Papasavvas I, Ambresin A, Pournaras JA, Henchoz L, Vaudaux J. Regression of Optic Disc Neovascularization (NVD) in a Patient with Behçet's Disease Treated with Oral Corticosteroids and Adalimumab (ADA). *Klin Monbl Augenheilkd*. 2019 Apr;236(4):578-580. English. doi: 10.1055/a-0800-8066. Epub 2019 Jan 7. PMID: 30616283.

- Roemer S, Bergin C, Kaeser PF, Ambresin A. Assessment of Macular Vasculature of Children With Sick Cell Disease Compared to That of Healthy Controls Using Optical Coherence Tomography Angiography. *Retina*. 2019 Dec;39(12):2384-2391. doi: 10.1097/IAE.0000000000002321. PMID: 30334922.
- Nguyen NCI, Fabro F, Ambresin A, Ezziat S, Bergin C, Mazzocato C, Mantel I. Factors associated with pain during intravitreal injection of anti-vascular endothelial growth factor. *Eye (Lond)*. 2018 Sep;32(9):1544-1546. doi: 10.1038/s41433-018-0126-z. Epub 2018 May 17. PMID: 29769650; PMCID: PMC6137149.
- Tam EK, Golchet P, Yung M, DeCroos FC, Spirn M, Lehmann-Clarke L, Ambresin A, Tsui I. Ischemic Central Retinal Vein Occlusion in the Anti-vascular Endothelial Growth Factor Era. *Retina*. 2018 Feb;38(2):292-298. doi: 10.1097/IAE.0000000000001546. PMID: 28207609.
- Daruich A, Matet A, Marchionno L, De Azevedo JD, Ambresin A, Mantel I, Behar-Cohen F. Acute Central Serous Chorioretinopathy: Factors Influencing Episode Duration. *Retina*. 2017 Oct;37(10):1905-1915. doi: 10.1097/IAE.0000000000001443. PMID: 28067724; PMCID: PMC5642321.
- Parvin P, Zola M, Dirani A, Ambresin A, Mantel I. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. *Graefes Arch Clin Exp Ophthalmol*. 2017 Nov;255(11):2127-2134. doi: 10.1007/s00417-017-3762-2. Epub 2017 Aug 10. PMID: 28798980; PMCID: PMC5640735.
- Kowalczyk L, Matet A, Dirani A, Daruich A, Ambresin A, Mantel I, Spaide RF, Turck N, Behar-Cohen F. Efficacy of intravitreal aflibercept in macular telangiectasia type 1 is linked to the ocular angiogenic profile. *Retina*. 2017 Dec;37(12):2226-2237. doi: 10.1097/IAE.0000000000001424. PMID: 28002269; PMCID: PMC5732636.
- Dirani A, Ambresin A, Marchionno L, Decugis D, Mantel I. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration. *Am J Ophthalmol*. 2015 Oct;160(4):732-8.e2. doi: 10.1016/j.ajo.2015.06.025. Epub 2015 Jul 2. PMID: 26144701.
- Ambresin A, Borruat FX. Hypertension artérielle et œil [Hypertension and the eye]. *Revue Médicale Suisse*. 2015 Dec 16;11(499):2366, 2368-72. French. PMID: 26852552.
- Matet A, Daruich A, Dirani A, Ambresin A, Behar-Cohen F. Macular Telangiectasia Type 1: Capillary Density and Microvascular Abnormalities Assessed by Optical Coherence Tomography Angiography. *Am J Ophthalmol*. 2016 Jul;167:18-30. doi: 10.1016/j.ajo.2016.04.005. Epub 2016 Apr 12. PMID: 27084003.
- de Massoungnes S, Dirani A, Ambresin A, Decugis D, Marchionno L, Mantel I. Pigment Epithelial Detachment Response to Aflibercept in Neovascular Age-related Macular Degeneration Refractory to Ranibizumab: Time Course and Drug Effects. *Retina*. 2016 May;36(5):881-8. doi: 10.1097/IAE.0000000000000813. PMID: 27115852.
- de Massoungnes S, Borruat FX, Ambresin A. Peripheral Bilateral Telangiectasiae in Multiple Sclerosis Patients Treated with Interferon B1a. *Klin Monbl Augenheilkd*. 2016 Apr;233(4):438-40. English. doi: 10.1055/s-0041-111803. Epub 2016 Apr 26. PMID: 27116503.
- Jang L, Gianniou C, Ambresin A, Mantel I. Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome. *Graefes Arch Clin Exp Ophthalmol*. 2015 Aug;253(8):1211-6. doi: 10.1007/s00417-014-2789-x. Epub 2014 Sep 30. PMID: 25267418.
- Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, Ambresin A, Mantel I. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. *Eye (Lond)*. 2015 Mar;29(3):450-1. doi: 10.1038/eye.2014.321. Erratum for: *Eye (Lond)*. 2015 Mar;29(3):342-9. PMID: 25762129; PMCID: PMC4366476.
- Ambresin A, Strueven V, Pournaras JA. Painless indirect argon laser in high risk proliferative diabetic retinopathy. *Klin Monbl Augenheilkd*. 2015 Apr;232(4):509-13. doi: 10.1055/s-0035-1545795. Epub 2015 Apr 22. PMID: 25902110.

- Dirani A, Mantel I, Ambresin A. Recurrent Macular Edema in Central Retinal Vein Occlusion Treated with Intravitreal Ranibizumab using a Modified Treat and Extend Regimen. *Klin Monbl Augenheilkd.* 2015 Apr;232(4):538-41. doi: 10.1055/s-0035-1545746. Epub 2015 Apr 22. PMID: 25902116.
- Ladaïque M, Dirani A, Ambresin A. Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab. *Klin Monbl Augenheilkd.* 2015 Apr;232(4):542-7. doi: 10.1055/s-0035-1545817. Epub 2015 Apr 22. PMID: 25902117.
- Lehmann-Clarke L, Dirani A, Mantel I, Ambresin A. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion. *Klin Monbl Augenheilkd.* 2015 Apr;232(4):552-5. doi: 10.1055/s-0035-1545783. Epub 2015 Apr 22. PMID: 25902119.
- Meier PG, Ambresin A, Thirkill CE, Borruat FX, Schalenbourg A. Paraneoplastic vitelliform retinopathy secondary to metastatic melanoma. *Klin Monbl Augenheilkd.* 2015 Apr;232(4):587-9. doi: 10.1055/s-0035-1545754. Epub 2015 Apr 22. PMID: 25902133.
- Mantel I, Niderprim SA, Gianniou C, Deli A, Ambresin A. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. *Br J Ophthalmol.* 2014 Sep;98(9):1192-6. doi: 10.1136/bjophthalmol-2013-304556. Epub 2014 Apr 10. PMID: 24729031; PMCID: PMC4145421.
- Casparis H, Wolfensberger TJ, Becker M, Eich G, Graf N, Ambresin A, Mantel I, Michels S. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study. *Retina.* 2014 Jan;34(1):12-7. doi: 10.1097/IAE.0b013e31829f74b0. PMID: 23945639.
- Mantel I, Ambresin A, Moetteli L, Droz I, Roduit R, Munier FL, Schorderet DF. Complement factor B polymorphism and the phenotype of early age-related macular degeneration. *Ophthalmic Genet.* 2014 Mar;35(1):12-7. doi: 10.3109/13816810.2013.766217. Epub 2013 Feb 1. PMID: 23373431.
- Ferrini W, Ambresin A. Intravitreal dexamethasone implant for the treatment of macular edema after retinal vein occlusion in a clinical setting. *Klin Monbl Augenheilkd.* 2013 Apr;230(4):423-6. doi: 10.1055/s-0032-1328388. Epub 2013 Apr 29. PMID: 23629796.
- Vaclavik V, Borruat FX, Ambresin A, Munier FL. Novel maculopathy in patients with spinocerebellar ataxia type 1 autofluorescence findings and functional characteristics. *JAMA Ophthalmol.* 2013 Apr;131(4):536-8. doi: 10.1001/jamaophthalmol.2013.1127. PMID: 23579607.
- Deli A, Moetteli L, Ambresin A, Mantel I. Comparison of fundus autofluorescence images acquired by the confocal scanning laser ophthalmoscope (488 nm excitation) and the modified Topcon fundus camera (580 nm excitation). *Int Ophthalmol.* 2013 Dec;33(6):635-43. doi: 10.1007/s10792-013-9749-z. Epub 2013 Mar 7. PMID: 23468053.
- Mantel I, Deli A, Iglesias K, Ambresin A. Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol.* 2013 Mar;251(3):697-704. doi: 10.1007/s00417-012-2090-9. Epub 2012 Jun 26. PMID: 22733165.
- Mariani A, Deli A, Ambresin A, Mantel I. Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol.* 2011 Nov;249(11):1635-42. doi: 10.1007/s00417-011-1734-5. Epub 2011 Jul 2. PMID: 21725716.
- Konstantinidis L, Mantel I, Zografos L, Ambresin A. Intravitreal ranibizumab in the treatment of predominantly hemorrhagic lesions in exudative age-related macular degeneration. *Klin Monbl Augenheilkd.* 2011 Apr;228(4):288-92. doi: 10.1055/s-0031-1273214. Epub 2011 Apr 11. PMID: 21484631.
- Moulin AP, Bucher M, Pournaras JA, Nguyen C, Ambresin A. Fluorescein and indocyanine green angiography findings in B cell lymphoblastic leukemia mimicking acute central serous chorioretinopathy. *Klin Monbl Augenheilkd.* 2010 Apr;227(4):342-4. doi: 10.1055/s-0029-1245251. Epub 2010 Apr 20. PMID: 20408096.

- Konstantinidis L, Ambresin A, Zografos L, Mantel I. Retinal pigment epithelium tears after intravitreal injection of ranibizumab for predominantly classic neovascular membranes secondary to age-related macular degeneration. *Acta Ophthalmol.* 2010 Nov;88(7):736-41. doi: 10.1111/j.1755-3768.2009.01547.x. PMID: 19604160.
- Konstantinidis L, Mantel I, Zografos L, Ambresin A. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy. *Eur J Ophthalmol.* 2010 Sep-Oct;20(5):955-8. doi: 10.1177/112067211002000524. PMID: 20306440.
- Konstantinidis L, Zografos L, Mantel I, Ambresin A. Optimal treatment of retinal angiomatous proliferation. *Graefes Arch Clin Exp Ophthalmol.* 2010 Feb;248(2):289. doi: 10.1007/s00417-009-1159-6. Epub 2009 Aug 21. PMID: 19693530.
- Konstantinidis L, Mantel I, Zografos L, Ambresin A. Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia. *Graefes Arch Clin Exp Ophthalmol.* 2009 Nov;247(11):1567-9. doi: 10.1007/s00417-009-1117-3. PMID: 19727795.
- Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). *Graefes Arch Clin Exp Ophthalmol.* 2009 Sep;247(9):1165-71. doi: 10.1007/s00417-009-1089-3. Epub 2009 Apr 29. PMID: 19404661.
- Polok B, Escher P, Ambresin A, Chouery E, Bolay S, Meunier I, Nan F, Hamel C, Munier FL, Thilo B, Mégarbané A, Schorderet DF. Mutations in CNNM4 cause recessive cone-rod dystrophy with amelogenesis imperfecta. *Am J Hum Genet.* 2009 Feb;84(2):259-65. doi: 10.1016/j.ajhg.2009.01.006. Epub 2009 Feb 5. PMID: 19200527; PMCID: PMC2668018.
- Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. *Graefes Arch Clin Exp Ophthalmol.* 2009 Mar;247(3):311-8. doi: 10.1007/s00417-008-0995-0. Epub 2008 Nov 29. PMID: 19043731.
- Mantel I, Zografos L, Ambresin A. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration. *Ophthalmologica.* 2008;222(5):321-3. doi: 10.1159/000144075. Epub 2008 Jul 11. PMID: 18617755.
- Mameletzi E, Pournaras JA, Ambresin A, Nguyen C. Retinal embolisation with localised retinal detachment following retrobulbar anaesthesia. *Klin Monbl Augenheilkd.* 2008 May;225(5):476-8. doi: 10.1055/s-2008-1027268. PMID: 18454403.
- Pournaras JA, Nguyen C, Vaudaux JD, Konstantinidis L, Ambresin A, Wolfensberger T. Treatment of central retinal vein occlusion-related macular edema with intravitreal bevacizumab (Avastin): preliminary results. *Klin Monbl Augenheilkd.* 2008 May;225(5):397-400. doi: 10.1055/s-2008-1027258. PMID: 18454380.
- Droz I, Mantel I, Ambresin A, Faouzi M, Schorderet DF, Munier FL. Genotype-phenotype correlation of age-related macular degeneration: influence of complement factor H polymorphism. *Br J Ophthalmol.* 2008 Apr;92(4):513-7. doi: 10.1136/bjo.2007.127811. Epub 2008 Jan 22. PMID: 18211923.
- Mantel I, Ambresin A, Zografos L. Retinal angiomatous proliferation treated with a combination of intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin. *Eur J Ophthalmol.* 2006 Sep-Oct;16(5):705-10. doi: 10.1177/112067210601600507. PMID: 17061221.
- El Matri L, Ambresin A, Schorderet DF, Kawasaki A, Seeliger MW, Wenzel A, Arsenijevic Y, Borruat FX, Munier FL. Phenotype of three consanguineous Tunisian families with early-onset retinal degeneration caused by an R91W homozygous mutation in the RPE65 gene. *Graefes Arch Clin Exp Ophthalmol.* 2006 Sep;244(9):1104-12. doi: 10.1007/s00417-005-0096-2. Epub 2006 Feb 28. PMID: 16518657.
- Nessi F, Guex-Crosier Y, Ambresin A, Zografos L. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to toxoplasmic chorioretinal scar. *Klin Monbl Augenheilkd.* 2004 May;221(5):371-3. doi: 10.1055/s-2004-812860. PMID: 15162283.

- Ambresin A, Wolfensberger TJ, Bovey EH. Management of giant retinal tears with vitrectomy, internal tamponade, and peripheral 360 degrees retinal photocoagulation. *Retina*. 2003 Oct;23(5):622-8. doi: 10.1097/00006982-200310000-00003. PMID: 14574245.
- Ambresin A, Tran T, Spertini F, Herbort C. Behçet's disease in Western Switzerland: epidemiology and analysis of ocular involvement. *Ocul Immunol Inflamm*. 2002 Mar;10(1):53-63. doi: 10.1076/ocii.10.1.53.10326. PMID: 12461704.
- Ambresin A, Shaarawy T, Mermoud A. Deep sclerectomy with collagen implant in one eye compared with trabeculectomy in the other eye of the same patient. *J Glaucoma*. 2002 Jun;11(3):214-20. doi: 10.1097/00061198-200206000-00009. PMID: 12140398.
- Ambresin A, Borruat FX, Mermoud A. Recurrent transient visual loss after deep sclerectomy. *Arch Ophthalmol*. 2001 Aug;119(8):1213-5. PMID: 11483096.

Educational publications

- Interview in: Koechlin S. Doktor KI in der Praxis. *Schweizer Familie*; 2026 Aug; pp. 56-61.
- Ambresin A, Bartolomeo N. *Netzhaut-Management mit Ultraweitwinkel-Bildgebung*. *Ophta* 5 / 2025; 2025 Nov.
- Ambresin A, Mermoud A, Mansouri K. Interview in: Clear Vision: Switzerland's Top Ophthalmologists Talk About the Possibilities of Modern Medicine. *Forbes Kazakhstan*; 2024 Dec 13.
- Ambresin A. *DMLA: mieux comprendre pour mieux agir*. REISO, Revue d'information sociale; 2025 Jan 2. URL: <https://www.reiso.org/document/13515>
- Ambresin A. Préserver sa vision face au diabète. *Salle d'attente #26*; 2024 Nov.
- Ambresin A. Eylea 8mg in clinical practice - experiences, case studies and expert opinions. Interview in: *Ophta*; 2024 May.
- Ambresin A. Schweizerische RWE-Studien zur nAMDTherapie sind für alle Partner in unserem Gesundheitssystem notwendig. In: RWE-Daten zu EYLEA: Wegbereiter für erfolgreiche Behandlungsstrategien bei therapienaiven nAMD-Patienten*innen. *Ophta*; 2024 Jan.
- Ambresin A. Eylea 2 mg Real-World-Evidence for XTEND study. Interview in: *Ophta*; 2023.
- Abdessemed C, Ambresin A. Diabète: surveillez vos yeux! *Lausanne Cités*; 2023 Nov 11.
- Ambresin A. DMLA sèche : la voleuse de vision silencieuse. *Salle d'attente*; 2023 Nov.
- Ambresin A. DMLA sèche: des progrès sont en vue. *Générations Magazine*; 2023 Nov.
- Prünke, C, Kurz-Levin, M, Ambresin, A. SimiMed Breakfast Meeting "Diabetic retinopathy in the ophthalmic practice" [Publication from panel discussion]. SOG Annual Congress, Lausanne, Switzerland. 2023 Sep 30.
- Ambresin, A. L'OMD, l'atteinte spécifique de la rétinopathie diabétique. Oedème Maculaire Diabétique « Il est temps d'y voir plus clair ». Brochure informative Roche. 2023:9.
- Retinal Physician Image of the Month, Benign Lobular Inner Nuclear Layer Proliferations (BLIPs) Of the Retina Associated with Congenital Hypertrophy Of the Retinal Pigment Epithelium, May 2023.
- Ambresin, A. Dépister la dégénérescence maculaire liée à l'âge. *Lausanne Cités*. 2023 Apr 5-6.
- Vabysmo® (Faricimab) Expérience et études de vie réelle des experts suisses, *Ophta* April 2023.
- Les maladies de l'œil liées à l'âge. Quelles solutions thérapeutiques ? 24 Heures, Tribune de Genève – Supplément Smart Media | Focus 50 Plus, 24 mars 2023.
- Œdème maculaire diabétique (OMD): l'information des patients est primordiale, *Salle d'attente, Newsletter n°17, Février 2023*.
- Ambresin A. Les complications oculaires du diabète. *Salle d'attente*. 2022 Sep 16.

- Soigner un patient diabétique: défis mutuels et durabilité, Salle d'attente – Newsletter, Novembre 2022.
- La DMLA touche entre 2% et 30% de la population, Aude Ambresin, Salle d'attente, Février 2022.
- Le traitement de la DMLA exsudative, Aude Ambresin, Salle d'attente – Newsletter, Février 2022.
- The importance of monitoring wet Age-related Macular Degeneration patients during Coronavirus disease 2019 pandemic: A retrospective study of assessment of functional and structural outcomes. G.N. Tsiropoulos, R. Vallée, D. Gallo Castro, A. Ambresin. Euretina, virtual meeting, 09-12 September 2021, Selected by Bayer for brochure publication.
- Images medical retina for the 9th Edition of Kanski's Clinical Ophthalmology: A Systematic Approach, John Salmon, Oxford, England. 2021.
- La dégénérescence maculaire liée à l'âge peut être ralentie, Aude Ambresin, Magazine Génération, Septembre 2021.
- Supervision de la rédaction de la brochure Explicare sur la DMLA Humide. June 2020
- Recommandation pour la pratique clinique pour la rétinopathie diabétique. Unisanté, Centre universitaire de médecine générale et de sante publique. Décembre 2019.
- Boussole DMLA: Imagerie multimodale pour le diagnostic et le traitement de la dégénérescence maculaire liée à l'âge (DMLA). 2019 ; Guidelines pour l'interprétation de l'imagerie oculaire pour les ophtalmologues dans le cadre de la DMLA. Projet conjoint avec Dr PD S Zweifel Université Zurich et Novartis. Novembre 2019.
- Images medical retina for the new Edition of Albert and Jakobiec's Principles and Practices of Ophthalmology, 4th edition, June 2019.
- Images medical retina for the new Edition of Kanski ophthalmology book. John Salmon, Oxford, England. Sept-November 2018.
- « Regard & Vision » Tribune de Genève & Le 24h Lausanne et sur le site www.mon-corps.ch 18 décembre 2019.
- Ambresin A, Borruat FX. Hypertension artérielle et œil. In: Les effets de l'hypertension artérielle sur l'œil [Adaptation]. Frossard C. Planète Santé [Online]; 2018 Jan 16. <https://www.planetesante.ch/Magazine/Cardiovasculaire/Hypertension/Les-effets-de-l-hypertension-artérielle-sur-l-oeil>
- Ambresin, A. Miscellaneous Retinal Disorders. In: Angio OCT in Everyday Ophthalmic Practice. Lumbroso B, Huang D, Marco Rispoli M. JP Medical Ltd; 2017. 192-3 p.
- Ambresin, A. Radiation Maculopathy. In: Optical Coherence Tomography Angiography of the Eye. Lumbroso B, Huang D, Waheed NK, Jia Y. Slack Incorporated; 2017.
- Rosselet P, Hagon-Traub I, Burnand B, Konstantidinis L, Ambresin A. Prévention et prise en charge de la rétinopathie diabétique - Prise en charge multidisciplinaire du diabète : recommandations pour la pratique clinique. Revue Médicale Suisse. 2017 Jun 7;13(566):1217.
- Ambresin A. Insights into RVO: Mechanisms of Action of Aflibercept. Eurotimes supplements. 2016 Apr 1.
- Ambresin A, Mantel I. AMD in 2016. Review article. Swiss Medical Forum. 2016;16(04):733-38.
- Ambresin A, Borruat FX. Hypertension artérielle et œil [Hypertension and the eye]. Revue Médicale Suisse. 2015 Dec 16;11(499):2366, 2368-72.
- Ambresin A, Zografos L, Mantel I. Antivasoproliferative Agents in Ophthalmology. Revue Médicale Suisse; 2010 Jan 13;6(231):51-4.
- Ambresin A, Mantel I. Révolutions thérapeutiques dans la prise en charge de la dégénérescence maculaire liée à l'âge. Tribune Médicale; 2008 Avr;18-21.

- Mantel I, Ambresin A. Ophtalmologie. La stratégie thérapeutique anti-VEGF améliore le pronostic visuel de la dégénérescence maculaire liée à l'âge exsudative. *Revue Médicale Suisse*; 2007 Jan 17; 7(94): 137-141.

Manuscript review for journals

- Expert Opinion on Biological Therapy
- Eye
- Journal français d'ophtalmologie
- Journal of Clinical Medicine
- Journal of Personalized Medicine
- Klimo Klinische Monatsblätter für Augenheilkunde (Klimo)
- Springer Nature Ophthalmology and Therapy

Broadcast media

- SALWEEN - 12 months results : use of Faricimab in patients diagnosed with PCV. Speaker service for: Roche. 2025 Aug; Switzerland. [Video]
- Le 9H-13H avec Hugo: Les portes ouvertes du Genolier Innovation Hub – Avec le Docteur Aude Ambresin, ophtalmologue. Radio One FM; 2024 Sep 28; Switzerland.
- In 100 % Santé – L'émission: [Diabète : prise en charge, dépistage et prévention](#). Lausanne FM ; 2022 Nov 11.
- With Journalist: Laurie Selli. *Chroniques Médicales*. Radio Lac et LFM; 2018.
- « Santé » : *Imagerie oculaire*. Tribune de Genève & Le 24H [Local newspapers]; 2019 Apr 30; Switzerland.
- World Diabetes Day: Special Focus on Diabetic Retinopathy. Swiss National Television (SFR/RTS); 2017 Nov.
- 36.9°: *DMLA*. Swiss National Television (SFR/RTS); 2014 Aug.
- In: *Emission Osmose. DMLA [AMD]*. Local TV; 2009 Feb; Switzerland.

Honors

- Zweifel S, Ambresin A, Eandi C, Menghini M, Garweg JG, Somfai G [Co-Principal Investigators]. Industry Grant (150,000 CHF) for AI-based Analysis of Retinal Imaging Data of Real-World Evidence in Switzerland. Roche; 2024; Switzerland.
- Barbosa M, Ambresin A. Benign Lobular Inner nuclear layer Proliferation (BLIPs) of the retina associated with congenital hypertrophy of the retinal pigment epithelium. In: *Ultra-widefield IM-AGE OF THE MONTH*. [Retinal Physician; 2023 May](#).
- Chitoroaga N, Ambresin A, Petrovic A. Challenges in Managing Post-lyell Ocular Complications: Addressing Severe Ocular Surface Disease During Intravitreal Injections. Nominee for: Théa Trophy Contest; 2023.
- Ambresin A. Industry Grant (29,940 CHF) for Database Creation of Patients with Atrophic Age-Related Macular Degeneration (AMD). Bayer; 2022; Lausanne, Switzerland.
- Ambresin A [Co-applicant]. Re-Equip Grant 362030_170792 for TopCorn Triton High-Resolution Imaging System for choroidal investigation. National Swiss Fund, FBM Lausanne University; 2017; Lausanne, Switzerland.
- Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, Ambresin A, Mantel I [Prize winners]. Two-year outcome of an observe-and-plan regimen for neovascular age-

related macular degeneration: how to alleviate the clinical burden with maintained functional results. Novartis Retina Price; 2015; Switzerland.

- Ambresin A. Research Grant (10,000 CHF) for Genotype–phenotype Correlation of Age-related Macular Degeneration; 2013.

Consultancy

- Abbvie
- Apellis
- Bayer
- Optovue
- Roche

Expertise

- Examiner for the EBO-EURETINA Imaging Subspecialty Exams. (2023-). Accredited by the European Board of Ophthalmology.
- Examiner for the EBO Retina Specialty Exam. (2026-). Accredited by the European Board of Ophthalmology.
- Abstract Reviewer of the Free Paper and e-Poster abstract submissions. 25th European Society of Retina Specialists (EURETINA) Congress; 2025 Sep 4-7 Sep; Paris, France.

Collaborations

- Moix Antoine Charl  lie, Holesz Sebastian, Amro Abdrabo, Eisele Elias. *OpenEye* : diagnostic de la r  tinopathie diab  tique utilisant des scans r  tiniens. EPFL/ETHZ; Lausanne/Zurich, Switzerland.
- Laforest, Timoth   (CEO). EarlySight; Geneva, Switzerland.
- RetinAI Medical AG; Bern, Switzerland.
- Hon. Prof Vanderberg (Associate Professor of Life Sciences), and Prof. Hilal Lashuel (Director of the Laboratory of Chemical Biology of Neurodegeneration). Brain Mind Institute, Swiss Federal Institute of Technology, EPFL; Lausanne, Switzerland.
- Prof. Panaretos. Institute of Mathematics, EPFL; Lausanne, Switzerland.